




 A review of the use of polyclonal intravenous immunoglobulin at a paediatric 
referral hospital in South Africa between 2009 and 2012 
 
This dissertation is submitted in partial fulfilment of the MPH (Hospital 




University of KwaZulu-Natal 
11/26/2014 
i 
A review of the use of polyclonal intravenous immunoglobulin at a paediatric referral hospital in 
South Africa between 2009 and 2012 
 
 
Submitted to:  
 
NELSON R. MANDELA SCHOOL OF MEDICINE 




In partial fulfilment of the academic requirements for the degree 
Master of Public Health, in the Discipline of Public Health Medicine 
School of Nursing and Public Health, College of Health Sciences 
University of KwaZulu-Natal 
 
The dissertation contributes 50% to the MPH qualification 
 
BY  
SHENAAZ RAIMAN, 9703187 
 
SUPERVISOR: 
DR. STEPHEN KNIGHT 
 
CO-INVESTIGATOR: 
DR. TYSON B. WELZEL 
 
2014, Cape Town 
 
Reference Number: BE071/12. College of Health Sciences, Biomedical Research Ethics Committee 




Polyvalent intravenous immunoglobulin (IVIG) is registered for a limited number of specific 
indications in South Africa but is increasingly being used for unregistered or off-label uses. No national 
evidence-based guidelines are available to guide clinicians with IVIG prescribing and against which 
use could be monitored. This results in IVIG being used in a range of clinical situations with 
questionable indications.  
Objectives and methods 
This study aimed to ascertain the registered and unregistered uses and cost of IVIG at a tertiary 
paediatric hospital in South Africa. A cross sectional descriptive study design was employed through a 
patient folder review, supplemented by data from the pharmacy electronic dispensing database, as well 
as the National Health Laboratory Service database. This study was conducted on all patients aged 0 to 
18 years who were issued IVIG during a 39 month period from 2009 to 2012 within this facility. 
Results and discussion 
During the study period, 185 patients received at least one dose of IVIG and a total 916 issues (3642g) 
were dispensed. Use fell into the Medicines Control Council registered indications in 76 (44%) patients 
involving 416 (48%) issues. Only 87 (53%) of the patients were tested for HIV and in these the HIV 
sero-prevalence was 19%. The cost per patient amounted to ZAR15 937 in South African Rand. The 
highest IVIG issue-values were for Guillain-Barré syndrome (ZAR301 586), primary 
immunodeficiencies (ZAR340 953) and ‘other transplants’ (ZAR546 708). The annual cost for 
IVIG/1000 admissions adjusted for inflation was ZAR24 294, ZAR24 847and ZAR60 251 for 
2009/2010, 2010/2011 and 2011/2012 financial years respectively. IVIG accounted for between 1.6%, 
1.7% and 4.6% of the pharmacy expenditure per year in the study period. 
Conclusion 
More than half of all IVIG issued at this paediatric hospital was used off-label. Considering the 
pressures on supply and the pharmaceutical costs, manifesting as an increasing share of the pharmacy 
budget, a more standardised, protocol-driven approach to the prescription of IVIG is called for. It is 
recommended that further reviews are conducted to determine the evidence-base for the use of IVIG in 
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Polyvalent human intravenous immunoglobulin (IVIG) is a polyclonal immunoglobulin collected from 
large pools of donated human plasma for intravenous use in South Africa. It provides antibodies for 
immunity for general diseases affecting the population from which it is derived. Consequently, the 
manufacturing, extraction and provision of this therapeutic product can be quite costly but can also lend 
itself to a wide and vague multitude of therapeutic modalities. The aim of this research study was to 
determine the actual indication for usage of IVIG at a paediatric hospital in the Western Cape, South 
Africa and to correlate this usage to registered and unregistered uses. In doing so, the researcher hoped 
to determine a baseline for further investigation into paediatric use and indications within the South 
African context. 
1.1.1 What needs to be known? 
To date, there have been no articles published from South Africa that describe the pattern and spectrum 
of usage of intravenous immunoglobulin in adults or in children. 
Red Cross War Memorial Children’s Hospital (RCWMCH) has shown an apparent trend of increased 
use of IVIG over the last few years. In order to gain an understanding of the indications of use of IVIG 
at the hospital, a retrospective audit on the dosages and indications for use was completed. 
1.2 RESEARCH QUESTION 
What were the indications and actual usage of polyvalent human intravenous immunoglobulin (IVIG) 
at a paediatric tertiary referral hospital in South Africa from January 2009 until March 2012? 
1.2.1 Why is the problem important? 
Polyvalent Intravenous Human Immunoglobulin is available in South Africa as Polygam® produced by 
the National Bioproducts Institute (NBI),[1] which until 2010 was the sole supplier of IVIG in South 
Africa. Recently, externally produced products have entered the local market, but are still relatively 
expensive.  
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In South Africa, high concentrations of IVIG are derived from pooled human plasma, sourced from 
non–remunerated blood donors. Demand has increased for a number of possible reasons, such as the 
following: a) there is a generally longer duration of use; b) the spectrum of usage has increased; or c) 
the number of patients for the traditional indications has increased. All in all, the demand on the 
suppliers has increased substantially (Appendix A). 
In 2010 the National Bioproducts Institute (NBI), the then sole South African supplier of IVIG, 
embarked on a major refurbishment process of its factory to cope with the increasing demand. The 
IVIG usage per 1000 population in South Africa is increasing (Table 1.1). In addition, most of the 
plasma harvested from blood donors in the country goes towards producing IVIG, to the point of 
redirecting plasma from other immunoglobulin preparations to meet demand. As an added measure, 
exports to the rest of sub-Saharan Africa have been limited or stopped. It is foreseen that demand will 
continue to outstrip supply.†  
Table 1.1: Grams IVIG used in South Africa per 1000 population 
Year   2001   2006   2011 
Grams IVIG per 1000 population 2.06 4.01 5.74 
Source: Personal communication: Trisha Chetty, Head: Information of NBI, Sept 2011) 
At national, provincial or hospital level, there is no standard policy guiding use and duration of IVIG 
therapy in this country that is known, other than for its registered uses. Anecdotal evidence suggests 
that the unregistered IVIG uses might outweigh its registered use. It is also not known whether clinical 
outcomes are measured routinely both for registered and unregistered use or whether the administration 
of IVIG has its defined and desired response.  
RCWMCH is a specialist paediatric state hospital in sub-Saharan Africa, with a catchment area that 
stretches beyond the provincial and national borders due to its specialist referrals. These specialist 
tertiary and quaternary areas include oncology, haematology, neurology, renal, and dermatology. 
RCWMCH has 290 beds with a busy outpatient service. The hospital reported having 23 210 
admissions in the 2009/2010 financial year, 22 380 in 2010/2011 and 22 551 admissions in the 
† Personal communication: Trisha Chetty, Head: Information of NBI, Sept 2011) 
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2011/2012 financial year. Privately funded patients also have access to these highly specialised services 
and differ in the proportions accessing various clinical services.  
Polyclonal IVIG is very expensive and has remained one of the top 50 cost drivers in the pharmacy 
budget for a number of years at RCWMCH. This evidence is obtainable through the electronic 
dispensing record called JAC at the pharmacy department for 2009-2014 (a monthly report lists the 
statistics for the top 100 drugs usage in the hospital). The high usage and increasing trend in using 
IVIG is mirrored in other tertiary referral centres in the Western Cape, which might result in 
successively larger percentages of the pharmacy budget being attributed to the purchase of IVIG. 
Whilst theoretically polyclonal IVIG is restricted in its use by the Provincial Code List within most 
state facilities, it is usually not known exactly for which indications polyclonal IVIG is used.  
It is not clear whether the increased use of IVIG is due to there being a greater therapeutic need for 
IVIG. If this is the case, alternate suppliers of the immunoglobulin would need to be sought in order to 
keep up with demand, as the current sole supplier is unable to increase production of IVIG according to 
this need.  
Alternatively, the increased demand may have resulted from inappropriate use of IVIG, despite there 
being suitable alternatives, or from the quasi experimental use of IVIG as a newer therapeutic solution 
for certain medical conditions. It is estimated that approximately 60 to 70% of IVIG use in adults 
complies with United States Food and Drug Administration (FDA)/approved indications.[2] A third of 
IVIG usage worldwide is purported to be attributed to indications for which there is scarce or no 
scientific evidence.[3] Within the paediatric context, the long-term risks associated with the injudicious 
use of IVIG in general are unknown, while the actual proportion of hypersensitivity reactions and other 
associated side effects from treatment at RCWMCH has also remained undocumented. 
Without all this information, pharmacy and management would be unable to formulate an evidence-
based policy for IVIG use at the hospital.  
1.2.2 How will the study solve the problem? 
Understanding the usage patterns and spectrum of use of IVIG at RCWMCH was integral to 
determining the frequency of its off-label (unregistered use). An analysis of the past indications, 
evidence for use and dosages used could assist in determining rationale for future use and duration of 
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evidence for use and dosages used could assist in determining rationale for future use and duration of 
use in a broader context. In addition, a pattern of disease profiles that warrants the use of IVIG (outside 
the registered use) in the paediatric setting could be established. The study was aimed at comparing the 
registered use with off-label use at RCWMCH.  
Finally, this study aimed at calculating the average annual per patient cost of IVIG, which could allow 
for future cost projections. Forecasting and the creation of a specific budget for the indications could 
allow for better control and management of IVIG. Ultimately, the aim was to fuel further studies in this 
field within South Africa and to enrich the knowledge base within the context of low and middle-
income countries and the populations they service. This could assist in the development of an evidence-
based guideline for the use of IVIG provincially and nationally in the South African context. 
1.3 PURPOSE OF THE RESEARCH 
The purpose of this research was to assess the use and indications for use of polyvalent human 
intravenous immunoglobulin at Red Cross War Memorial Children's Hospital, a tertiary paediatric 
hospital in South Africa, for the period January 2009 to March 2012, to provide baseline data that 
would guide the development of evidence-informed guidelines for its future use. 
1.3.1 Specific objectives of the research 
The specific objectives of the study were to do the following: 
1. Describe the total annual usage of IVIG;  
2. Describe the demographic profile of children who have received intravenous immunoglobulin 
therapy;  
3. List the main indications for usage as recorded in patient folders and/or by relevant clinicians’ 
judgement; 
4. Correlate the indications for intravenous immunoglobulin therapy to registered and off-label use 
recommendations during this time period; 
5. Determine the expenditure on immunoglobulin therapy and relate this to the total drug 
expenditure during each financial year;  
6. Calculate the annual cost and cost per patient for forecasting pharmacy budgets; and 
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7. Identify the unregistered indications for IVIG for which treatment protocols need to be 
developed.  
1.3.2 Assumptions underlying the study 
This study was conducted with the assumption that despite the large amount of IVIG used at 
RCWMCH, 80% of the time it was used for registered indications during the time period January 2009 
until 31 March 2012. 
1.3.3 OPERATIONAL DEFINITIONS USED IN THE STUDY 
The only indications that might differ from the standard definitions include the following: 
• Registered indication: An indication for IVIG registered with the Medicines Control Council of 
South Africa and as listed in IVIG the package insert 
• Off-label: Medication that is being used for an unlicensed or unregistered indication as per 
package insert approved by the Medicines Control Council of South Africa or other relevant 
registering body in context 
• Issue: A dose of IVIG dispensed in any of its varied strengths and recorded against a patient 
name in the pharmacy dispensing database 
• Admission: Patients admitted to RCWMCH with the length of stay >1 day 
• Patient day equivalent (PDE): Patient days + 1/3 outpatient / service group / casualty headcount. 
• Average length of stay (ALOS): Patient days/separations (discharges/day patients/deaths/ 
external transfers out) 
• Cost per patient: Total expenditure / PDE 
• Haemovigilance: An organized system of surveillance throughout the transfusion chain 
intended to evaluate information in order to prevent the appearance or recurrence of adverse 







Polyvalent human intravenous immunoglobulin (IVIG) has been used to treat several groups of 
conditions including primary immunodeficiencies, secondary immunodeficiencies, autoimmune 
diseases and neurological disorders. Several countries including the United States, United Kingdom, 
Canada and Australia have published evidence-based guidelines for the administration of 
immunoglobulin therapy. [4],[5],[6],[7] In South Africa, IVIG is registered for a narrow spectrum of 
indications.[8]  However, beyond these registered indications, no evidence-based guideline exists that 
could guide the clinician through the multitude of off-label or unlicensed indications. Individual 
clinical judgement determines consideration and use at the RCWMCH but such subjectivity can lead to 
varied, expensive and occasionally indefensible practice.  
A brief history of the mechanism of action, origin, history, manufacture and global picture is essential 
for greater understanding of the need for IVIG. This chapter discusses the literature that was reviewed 
in an attempt to gain insight into the various aspects contributing to IVIG production, its use and 
indications within the global and South African context. An extensive review was also conducted to 
identify other similar studies that have been conducted within South Africa or beyond and the results 
were tabulated and compared in a summarised review. 
2.1.1 What is intravenous immunoglobulin (IVIG)? 
Polyclonal human IVIG is a plasma protein replacement therapy containing large concentrations of 
varying subclasses of IgG (Immunoglobulin G) antibodies as well as minute quantities of IgA 
(Immunoglobulin A) and IgE (Immunoglobulin E) found naturally in human plasma. It is obtained 
from pooling the plasma of no less than 1000 non-remunerated blood donors per batch and then 
subjecting the plasma to a stringent fractionation and pasteurisation process to obtain the final useable 
product.[9]  These IgG molecules reflect the collective acquired immunity of the donor pool from which 
it is derived.  
Approximately 25 commercial products are available globally. These are however not considered 
generic to one another, due to the variances in source, manufacturing processes and ultimately 
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product.[10]  The therapeutic efficacy is not the same for each unit of IVIG used. There are varying 
concentrations of immunoglobulin and IgG subclasses and hence antibody titre, as well as differing 
infusion rates and side effects. In addition, the various IgG formulations are thought to include small 
amounts of soluble CD4 cells, cytokines, soluble cytokine inhibitors, major histocompatibility complex 
and stabilising agents that exhibit their own independent effect as determined from the donor plasma 
pool.[11] 
Consequently, whilst all these products are therapeutically effective, the concentration and uses may 
differ in minor ways in the country in which they are registered. [12] 
The mechanism of action of polyclonal IVIG is multifaceted, lending itself as a therapeutic medium to 
a wide array of disease states, as is evident in Table 2.1 and Appendix A. 
Table 2.1: Mechanism of action of polyclonal IVIG 
• Modulation of complement activation;  
• Saturation of idiotypic antibodies; 
• Suppression of Fc receptors on macrophages and activation of dendritic cells to mediate anti-
inflammatory effects helping to reduce the severity of the autoimmune disease or inflammatory 
states; and  
• Suppression of a multitude of inflammatory mediators including chemokines, cytokines and 
metalloproteinases.[13],[14] 
Source: Adapted from Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory 
diseases with intravenous immune globulin. N Engl J Med. Sep 6 2001;345(10):747-55. 
For this reason, IVIG has an important role in the treatment of auto-immune and immune deficiency 
states by conferring a passive immunity, while also acting as an immunomodulator. These various 
mechanisms may be important in the different therapeutic uses of IVIG, including (1) replacement 
therapy for primary and secondary immunodeficiencies, i.e. antibody deficiencies; (2) specific passive 
immunotherapy; and (3) management of specific inflammatory and/or immunologic disorders. The 
complete mechanism of action of IVIG, however, is not fully understood and further research is on-
going with evidence for greater therapeutic outcomes with use in other infectious disease states as well 
as other autoimmune conditions coming to the fore.[15] 
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IVIGs have shown to be beneficial in a number of primary immune deficiency disorders, including B-
cell and T-cell disorders, and combined T-cell and B-cell immune deficiencies (Table 2.2). Patients 
with primary immune deficiency disorders are usually at increased risk for respiratory infections, 
particularly with Pneumococcus sp. and Haemophilus influenza; for gastrointestinal infections, 
particularly with Campylobacter sp., rotavirus, or Giardia sp. and for infections of the urinary tract. [16], 
[17], [18]  
Table 2.2: Primary immune deficiency disorders known to respond to intravenous 
immunoglobulin replacement therapy 




(complete thymic aplasia) 
Lymphopaenia; T helper cell deficiency resulting 
in poor antibody production 
Hyper IgM syndrome Deficiency of IgG, increased IgM; defect in 









Combined T- and 
B-lymphocyte 
disorders 
Wiskott-Aldrich syndrome Low IgM; poor antibody production 
Ataxia telangiectasia Low IgA; poor antibody production 
Severe combined 
immunodeficiency 
Agammaglobulinaemia with severe T-cell defects 
Source: Adapted from Ballow M. Intravenous Immunoglobulins: Clinical Experience and Viral Safety. J Am 
Pharm Assoc. 2002;42(3). Accessed online from http://www.medscape.com/viewarticle/436640_2 on 12 March 
2014.[19]  
Secondary immune deficiencies are sometimes associated with B-cell malignancies, leading to severe 
and recurrent bacterial infections. These infections are particularly serious when serum IgG levels 
decrease to < 6.4 g/l. [20], [21] IVIG has shown to be beneficial for these patients at high risk for 
secondary and complicated infections.  
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2.1.2 History of IVIG 
The initial use of immunoglobulins occurred unbeknownst to the users in the 1800s, in form of animal 
sera. Clinicians used animal sera to treat smallpox, rabies and diphtheria without patient knowledge or 
consent. Success was variable and treatment failure, serum sickness and/or death were common. The 
first specific use of antibodies themselves was in the 1930s, when they were derived from human 
placental material to treat measles. [22] 
However, it was not until the 1940s when Sr. Edwin Cohn was given the task by the National Research 
Council of the United States of America (USA) to create a readily available blood product, albumin, for 
the treatment of shock. Cohn developed a large scale fractionation process for the separation of plasma 
proteins by treatment with cold ethanol, salt, pH, temperature and centrifugation. The Cohn-Oncley 
cold alcohol fractionation process is still in use today for the production of immunoglobulins. [23]   
Immunoglobulins derived from human plasma were first used in 1952 and given intra-muscularly to 
treat auto-immune conditions, including hypogammaglobulinaemia. [21] However, due to large volumes 
required and slow absorption from the injection site, the treatment proved very painful and not 
sustainable. Experiments with intravenous immunoglobulin in the 1960s yielded large scale systemic 
reactions and adverse events due to complement activation of the protein aggregates, prekallikrein 
activator and contamination by impurities. In 1982, anion exchange chromatography was successfully 
used for the purification of IVIG and resulted in a more stable and unmodified IgG component, as well 
as inclusion of IgG subclasses. [20] 
In 1981, intravenous IgG was used to treat idiopathic thrombocytopaenic purpura (ITP) for the first 
time, with success. [24] The following year, the World Health Organisation (WHO) implemented a 
minimum standard for the manufacture of IVIG products. The main criteria for production include the 
following: 
• The production batch should be prepared from a pool of at least 1000 donors. 
• The batch should contain at least 90% intact IgG and as little IgA and IgM as possible. 
• IgG subclasses should be present in a distribution similar to natural plasma (WHO reference 
plasma: IgG1 [60%]; IgG2 [29.4%]; IgG3 [6.5%]; IgG4 [4.1%]). 
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• The level of antibody against at least two bacterial species and two viruses should be 
ascertained; additionally, the IVIG should have at least 0.1 i.u. of anti-Hepatitis B surface 
antigens (HBsAg) and a radioimmunoassay titre of 1 to 1000 per ml of anti-Hepatitis A (HAV) 
virus.  
• The preparation should be free of fragments and aggregates, as well as prekallikrein activator, 
kinins, plasmin, accumulating preservatives, and other damaging contaminants. 
• The immunoglobulin should be modified biochemically as little as possible 
• The immunoglobulin should retain opsonizing and complement-fixing activities and other 
natural biologic characteristics. [25] 
Since 2006 technological developments in the manufacture of immunoglobulin have resulted in the 
preparation of a sub-cutaneous immunoglobulin (SCIG). The SCIG dosage form assists patients 
needing chronic therapy such as patients with primary immunodeficiency disease (PIDD) and patients 
unable to make immunoglobulin requiring replacement therapy, by preventing serious bacterial 
infections. The advantages of this dosage form over IVIG and intramuscular immunoglobulin (IMIG) 
include the following: 
• Minimisation of adverse effects associated with IVIG; 
• Less painful than IVIG or IMIG; 
• Is therapeutically equivalent to IVIG; 
• Transfusion time is greatly reduced and obliterates the need for vascular access; 
• Can be self-administered at home, thereby decreasing the need for a hospital admission for 
administration as with IVIG; 
• Fewer side effects experienced, like fevers, myalgias, headache, chills and 
• More cost effective in long-term therapy. 
However, most low to middle-income countries are confined to usually one manufactured product of 
IVIG and have not seen SCIG enter the market as yet. In addition, sub-cutaneous products showed 
greater localised site reactions and should not be considered in non-compliant patients.[26] 
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• Manufacturing, donors and safety issues 
Subsequently, various manufacturing steps and techniques have been added to prevent viral 
transmission and re-aggregation of its proteins. Whilst bacteria and protozoa may contaminate blood 
products, potentially blood-borne viruses are the major infectious risk in the product. Bacteria and 
protozoa are unlikely to survive the cold ethanol precipitation procedure used to produce 
immunoglobulin. However, a small risk of viral infection from human plasma preparations can never 
be entirely ruled out. IVIG produced in 1993 and 1994 was subsequently responsible for over 125 cases 
of Hepatitis C infection (HCV).[27]  Whilst this was the only known and documented outbreak, an effort 
to increase the quality and safety of plasma derived products is one of the key components of IVIG 
manufacture. Many health authorities, including the WHO, have issued guidelines outlining the 
requirements for the collection, processing and quality control of blood, blood components and plasma 
derivatives. These guidelines refer extensively to the following factors: 
• Quality of plasma collected 
The careful selection of donors is essential. A careful medical examination and viral testing are 
preliminary requirements in plasma donation centres. In addition, anonymous questionnaires for 
eliminating high risk donors are administered. The locations of donor facilities are carefully 
considered. Collection from donors in countries where there is a high prevalence of blood borne 
diseases is now avoided and data from collection centres in the early 1990s showed low annual 
prevalence for HIV, Hepatitis B virus (HBV) and HCV. [28]  In addition there have been higher trends 
of blood borne diseases or HCV antibodies in remunerated donors compared to non-remunerated 
(volunteer) donors in certain localities in the USA.[9] 
The WHO guidelines encourage volunteer or unpaid donation of blood and plasma. The frequency of 
donation is controlled by quarantine of plasma of new or first time donors for a few months until 
subsequent testing has eliminated any contaminated or infectious plasma. The danger of frequent 
plasma donation by the same donor is that plasma could be donated whilst a blood borne disease is in 
its window period and thus it is necessary to create a database of screened and regular volunteer blood 
or plasma donors. As a result of some of these factors, the diligent but necessary screening of donors 
can reduce the plasma pool base subsequently. 
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• Stringent screening process of donated plasma for infectious agents 
Introductory screening tests for blood or plasma donors include individual tests for HBsAg, Anti-HCV, 
Anti-HIV-1 and -2, syphilis serology and Alanine Transaminase (ALT). Table 2.3 below shows some 
of the viruses that can be eliminated by scrupulous donor and plasma screening. Due to possible 
inconsistencies in specificity and selectivity of antibody assays, several immunoglobulin manufacturers 
are now investigating polymerase chain reaction (PCR) based assays for plasma testing. The PCR-
based assays work by detecting viral genomic material through nucleic acid amplification and can 
therefore detect viruses that may have otherwise escaped antibody detection tests. For example, 
Aventis in the USA developed a PCR-based assay that detects viral nucleic acids from HCV, HBV, and 
HIV-1. The company uses it to test small plasma pools in new drug mechanism experiments. This test 
is capable of detecting virus loads of ≥1.2 x 103 genome equivalents (GE)/ml of HBV, ≥8.4 x 103 
GE/ml of HCV, and ≥4.9 x 103 GE/ml of HIV-1 with 95% confidence. The assay is well suited for 
plasma pool testing, and the data demonstrates that it is sensitive and reproducible. [29]¸ [30] 
Recently, the European Committee for Proprietary Medicinal Products recommended screening of 
immunoglobulin preparations for HCV Ribonucleic Acid using PCR-based tests.[18]  
Table 2.3: Ease of transmission via immunoglobulin therapy 
 
Eliminated by careful donor screening/testing: 
Hepatitis B virus 
HIV 1 & 2 
Known to be relevant: 
Hepatitis C virus 
Unknown: 
sporadic Creutzfeldt–Jakob diseases (spCJD) 
variant Creutzfeldt–Jakob disease (vCJD) 
Protection by high titres of neutralising antibodies: 
Parvovirus B19 
Hepatitis A virus 
Not clinically relevant but transmitted: 
Hepatitis G virus 
Transfusion transmitted virus 
Source: Adapted from Helen M. Chapel for the IUIS Committee on Primary Immunodeficiency Disease[10] 
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• Accreditation of manufacturing facilities and donor blood centres 
The production of plasma products has been regulated by good manufacturing principles and 
mandatory repeated inspections since the late 1980s in the USA. Any change in the immunoglobulin 
production process requires repeated inspections by regulators. Accreditation and regulation have led to 
some companies closing due to insufficient funding. This resulted in a gross shortage of 
immunoglobulin in the late 1990s that was felt globally. [9]  
• Additional viral elimination steps in manufacture 
The dominant manufacturing method in the production of immunoglobulin remains the Cohn’s Alcohol 
Fractionation process (Also known as Cohn-Oncley cold alcohol fractionation process (Figure 2.1). 
This process uses the various solubilities of plasma proteins through heat, pH and ethanol concentration 
to partition out the fractions through centrifugation. This process is utilised to manufacture not only 
immunoglobulins but also Factor VIII, fibrinogen and the initial goal for this process, albumin.  
The Cohn-Oncley’s process is also capable of inactivating and reducing viruses like HIV-1, HIV-2, 
Pseudorabies virus, HBV and Simian virus as an adjunct to the fractioning methods. However, lipid 
coated viruses and enveloped viruses like Parvovirus B19 and Hepatitis C virus are not effectively 
inactivated. Hence, the WHO guidelines require that additional steps be used for further inactivation of 
enveloped viruses and elimination of the immunoglobulin precipitate. The methods used are varied and 
include solvent/detergent processes, dry heat, pasteurisation, heat-treatment of freeze dried products, 
incubation at low pH, enzyme treatment (pepsin), nanofiltration, chromatography and caprylate 
precipitation.[31]  
Excipients like sucrose may be added to the plasma pool to prevent aggregation of the 
immunoglobulins at higher temperatures. The aggregation of globulins has been associated with 
adverse effects like fevers, chills, tremors and pain. Excipients add stability to preparations but cause 
changes in pH, osmolality, dextrose content, etc. Interestingly, different methods in conjunction with 
the Cohn-Oncley cold alcohol fractionation process result in different outputs and yield of intact 
immunoglobulin monomers. 
Consequently, depending on the donor pool, method of manufacture, excipients utilised, anti-viral steps 
employed, each product of IVIG is not the generic equivalent of any other. In the USA, the varied 
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registrations of IVIG products allow different products to be used selectively, according to each 
patient’s disease profile and needs. [32] 
 
Figure 2.1: Cohn-Oncley cold alcohol fractionation process 
Source: Adapted from Buchacher, A; Iberer, G. Purification of immunoglobulin G from human plasma: aspects 
of yield and virus safety. Biotechnology J. 2006. 1, 148-163.[33] 
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2.1.3 Side effects and adverse effects 
IVIG has been a relatively safe product, due to the strict controls placed upon its manufacture and 
subsequent viral screening. There has been no known or documented transmission of HIV via an IVIG 
infusion. Adverse effects have been associated with infusion issues rather than the product itself. As 
some products contain sucrose (for disaggregation), these risk renal failure, particularly in diabetic 
patients, septic patients, the elderly, and patients with any pre-existing renal insufficiency.[5],[19]  
As highlighted above, different products exist internationally that allow for individual selection of a 
particular IVIG solution to match the patient’s profile. In the South African context, where there is one 
major national supplier, this matching cannot take place. Hence, when the benefit of administration 
outweighs the risk, due diligence must be given to monitoring and investigation for any adverse effects 
after infusion.  
Mild side effects of IVIG include: headache, nausea, abdominal pain, myalgias and arthralgias; 
urticaria and other rash conditions; chest discomfort and tachycardia; low grade fever and chills; and 
flushing. These can be treated by slowing down the infusion rate or pausing the infusion temporarily 
until symptoms resolve. Utilising an alternative product, if available, may also be worth considering. In 
some cases mild steroids, antihistamines and analgesics may also be considered to resolve some of 
these minor side effects. [5], [19] 
Major side effects include aseptic meningitis syndrome, acute renal failure, thrombo-embolism, 
myocardial infarction and anaphylaxis. Aseptic meningitis syndrome has been associated with IVIG 
use in patients with a history of migraine prior to infusion. Adequate hydration, slower infusion rates 
and treatment with analgesia and migraine medication can help to prevent this complication. If 
discontinued, the symptoms and resulting effects are reversible. The elderly, in whom cerebral or 
cardiac ischaemia may co-exist, the overweight and/or severely hypovolaemic patients are more prone 
to thromboembolism.[5] 
Finally, IVIG must be given with caution to patients who have pre-existing antibodies to IgA or who 
have IgA deficiencies. This is due to the small amount of IgA that can be present in polyclonal IVIG 
products, resulting in sensitisation and anaphylaxis to the antibodies of IgA or other IgA particulate 
matter that might be present. Reactions to IgA in IgA deficient patients usually happens 30 to 60 
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minutes post IVIG administration. Levels of IgA should be determined particularly in primary 
immunodeficiency states like hypogammaglobinaemia or agammaglobulinaemia.[19] 
Rare but potentially serious side effects include serum sickness, haemolytic anaemia, leukopaenia or 
neutropaenia and pulmonary oedema. 
Stringent regulations in donor screening, manufacturing processes, regulation and accreditation have 
put a strong focus on quality and safety. Particularly in low and middle-income countries, there is a 
need to afford more stringent monitoring and evaluation post administration to determine adverse 
events. Haemovigilance strategies need to be adopted pre- and post-administration.[19] 
2.1.4 Global demand 
IVIG has been the major driver in the plasma products industry due to an increasing usage thereof for a 
multitude of clinical indications. Many of these indications are new and have only been considered in 
the past few years. Currently major IVIG users are in high-income countries: North America and 
Europe have approximately 20% of the world’s population but use approximately 75% of all IVIG 
produced globally. Unmet needs in low-income countries, as well as emerging markets, are likely to 
increasingly fuel the need for IVIG in years to come.[34]  
In 2009 the global demand for plasma-derived products was estimated to be US$11.8 billion. Of this, 
46% was attributed to the cost of IVIG (US$5.4 billion), albumin 10% and Factor VIII 9%. It is 
estimated that immunoglobulins are likely to exceed US$9.0 billion by 2018 (notwithstanding 
registration for new indications in high-income countries). 
The following are some of the reasons for an increasing demand: 
• Increase in global population; 
• Rise in global per capita GDP and rise in health expenditure; 
• Increased ageing population; 
• Increasing awareness of the benefits of immunoglobulins clinically; 
• Proposed registrations of new indications for use; 
• Increase in diagnosed bleeding disorders and identification of primary immune deficiencies and 
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• Greater off-label use of IVIG.[35], [33] 
Worldwide supply and demand of plasma and plasma-derived medicine 
There was an average annual increase of approximately 12% in the use of IVIG from 1984 to 2008. 
Thereafter the global growth rate in IVIG use is about 7% annually due to more stringent and good 
manufacturing principles being enforced that negatively affected supply. Consolidation of industries 
led to enhanced product safety and efficiency. Some high-income countries like Australia are currently 
seeing a growth of about 10%. In low to middle-income countries, data does not currently exist on 
annual usage. [36] 
Approximately 82 tons of IVIG were consumed worldwide in 2008 and 120 tons were estimated to 
have been used in 2012. Use is estimated to rise to about 132 tons globally by 2015 (Table 2.4). The 
shortage of plasma-derived medicines and in particular IVIG has had the most impact in low and 
middle-income countries. High costs for production, long production times (6-8 months) as well as 
shortages in plasma from available donors contribute to this shortage. In addition, both the on- and off-
label uses are generally for rare indications for which health budgets in developing countries are unable 
to allocate sufficient resources.[37] 
Table 2.4: Global IVIG demand from 2006 to 2015 (Metric tons) 
Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
IVIG is approved for Alzheimer’s disease treatment in 2012 
Metric tons 68 75 82 88 94 100 107 120 135 151 
Annual growth rate  10.% 9% 7.% 7.% 7.% 7.% 12.% 12.% 12.% 
IVIG is not approved for Alzheimer’s disease treatment in 2012 
Metric tons 68 75 82 88 94 100 107 115 123 132 
Annual growth rate  10% 9% 7% 7% 7% 7% 7% 7% 7% 
Source: Adapted from Robert P. Global Plasma Demand in 2015. [39] 
IVIG usage is currently highest in the USA, followed by Sweden, Austria and France. In addition 
developing markets like China and Japan are likely to fuel the demand for IVIG further. One important 
additional consideration that is likely to increase demand excessively is that clinical trials for the use of 
IVIG in Alzheimer’s have been underway since 2009. Interim results are showing promise with 
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definite results expected within the next few months. Consequently, there is a pending FDA registration 
for such use. In the USA it is estimated that at least 2.4 million people are afflicted with Alzheimer’s. 
Almost every country imports plasma with the exception of the USA which is able to sustain its supply 
through a remunerated plasma donor process. [38], [39] 
In 2007, approximately 26 million litres of plasma was fractionated globally. Of this about 9 million 
litres were recovered plasma from blood donation and about 18 million litres were sourced by 
plasmapheresis through plasma donation. Only 72.5 metric tons of IVIG were produced yielding 2.8 
gram per litre.[41] Yield outputs vary depending on the manufacturing process used, the viral 
elimination methods employed, the quality of blood donation and plasmapheresis, maintenance of cold 
chain procedures, regulation and accreditation of good manufacturing practices by the production  
plants. Often producers have to outweigh risks of high output with safety of product. For example, 
some viral elimination methods utilise heat which also destroys the IgG monomers at these 
temperatures rendering the product yield safe but low. As of 2012, 1 litre of plasma yielded 
approximately 3.3 grams of IVIG. Of the 78 fractionating plants that existed in the world in 2010, the 
majority were located in Europe and China. [33], [34], [35], [36] 
Specific issues in middle and low-income countries on supply and demand include: the availability and 
affordability of blood and blood products; poor regulation and guidance on blood products; the 
potential risk of transfusion transmitted diseases; lack of reporting systems; and wastage of plasma due 
to ineffective mechanisms for safe screening and manufacturing. 
The World Health Organisation has listed IVIG as an essential medicine for children, particularly for 
the indication of primary immunodeficiency where it is lifesaving.[40] The Achilles Project was 
developed by the WHO to assure the safety and availability of blood products in developing countries. 
Members of the World Health Assembly were encouraged to implement a set of guidelines on the 
collection of blood products, screening manufacturing, fractionation, viral removal and other blood 
product associated criteria to ensure safety and quality of the blood products. The key role was to 
encourage developing countries to create their own fractionation plants (government funded) and to 
establish a safe and sound donor volunteer programme for plasmapheresis. To this end, the WHO made 
available numerous guidelines on these processes, assisted with accreditation of facilities and the 
training of quality and safety inspectors, offered standardised regimens and encouraged the 
harmonisation of regulations relating to the production of IVIG.[41] 
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The production of a sufficient quantity of qualified and safe plasma is the solution to global shortages. 
The WHO sees the creation of independent fractionation plants as the only way of sustaining the need 
for plasma-derived products. In low and middle-income countries in particular, there is an inherent 
need to recover all plasma available in the country and initiate a source plasmapheresis programme. 
Current trends show an inability to cope with current demands globally, let alone the newer indications 
coming to the fore in years to come. It is highly unlikely that costs for productions are going to 
decrease. As it stands, IVIG in South Africa is currently unaffordable for many chronic conditions such 
as chronic inflammatory demyelinating polyneuropathy (CIDP), primary immunodeficiencies both in 
private as well as in public budgets. As a result, IVIG should be restricted in its use to life threatening 
and registered indications until a greater capacity is developed for increasing yields and recovery of 
IVIG.[33], [35], [37], [39] 
2.1.5 The South African context 
In South Africa the sole supplier of polyclonal IVIG is the National Bioproducts Institute. Established 
as a non-profit organisation in 2004, it is involved in the production of blood transfusion products 
nationally. Due to increasing demands for IVIG and other blood products, NBI in 2010 embarked on a 
major refurbishment process to their production plant. Currently three other Immunoglobulin G (IgG) 
products are registered: intramuscular IgG products like Intragam®, and Beriglobin® unsuitable for 
higher doses, and since 2012, intravenous Octagam®. Intraglobin F® was briefly available via special 
application from the MCC (section 21 approval). Red Cross War Memorial Children’s Hospital had to 
make use of this in 2011 when Polygam® was unavailable in the quantities required. NBI is reliant on 
a volunteer blood donor programme through the South African National Blood Transfusion Services 
and Western Province Blood Transfusion Service as well as other international suppliers. The plasma is 
screened for hepatitis B surface antigen, HIV-p24 antigen, and antibodies to syphilis, HIV-1, HIV-2 
and hepatitis C (Appendix B). Parallel importation as well as the need for alternative suppliers of IVIG 
could result in greater competition; products with more specific indications; could sustain supply, as 
well as assist in more viable pricing.  
South Africa currently has a dual public and privately funded healthcare system. Approximately 84% 
of all South Africans, generally lower income and unemployed citizens, make use of the public health 
medical service whilst higher income groups access their own private medical care.[42] 
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A provincial code list is developed by clinical and pharmaceutical heads of state facilities containing 
drugs on national tender that meet these public health priorities. This code list of drugs is regularly 
updated and revised to meet the current demands based on the scientific evidence presented in 
motivations by local clinicians. 
The public system is geared towards prioritising key health issues to meet the need of the majority of 
the public, but cannot fully address individual and rare disease conditions adequately at all times. The 
public health system in South Africa is organised in different levels of care, namely primary, 
secondary, district and tertiary level of care where a referral system exists for appropriate service of 
care at each level. Drugs are restricted for use by the level of health service offered. In the Western 
Cape, usage of IVIG is restricted to central and tertiary level healthcare facilities for paediatrics and 
specialist usage only. Patients who need IVIG would have to be referred to these institutes. 
Occasionally, secondary level hospitals have reluctantly issued IVIG as it erodes the budget of these 
facilities greatly and requires them to purchase IVIG outside the coding restrictions.  
Polyclonal IVIG is expensive, costing between ZAR362 (2009) and ZAR469 (2014) per gram IVIG at 
state level and approximately 20% more in private health facilities. In some private facilities IVIG is 
approximately ZAR659 per gram (2014) but this is determined by individual facilities and varies with 
different private institutions based on the single exit pricing system.‡ The above costing excludes any 
additional expenses incurred by the infusion itself, bed occupancy within a ward and any supportive 
therapy. Rather than being restricted by a provincial code list, usage in private is determined by what 
the funder is willing to cover and pay for. Different medical funders offer varying levels of cover and 
have established norms for their own usage (Appendix C).  
With clinical research continuously expanding the potential applications of IVIG, the concern for 
increasing demand and inadequate supply is valid. The broad mechanism of action allows IVIG as a 
therapeutically viable choice and often last resort in many disease and infectious conditions. Whilst 
attempts have been made to document the unregistered use in various institutes internationally, no such 
audit has been documented within South Africa. 
‡ Incidentally, it is interesting to note that the gold price per gram ranged from around ZAR250 (2009) and ZAR420 in this 
time period of the study. Currently the gold price per gram is ZAR432.(November 2014) 
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The South African government has embarked on a project of rolling out a national healthcare plan that 
allows for broader quality access to healthcare for all. The plan is for this social healthcare net called 
the National Health Insurance (NHI) to be rolled out over a period of 14 years, starting with a pilot 
project from 2012 to 2017 in five health districts. Essentially it involves amalgamating the public and 
private systems from a human resource, equipment and facility point of view. One of the areas that will 
need harmonisation is that of a national system of rational drug use.[32], [33], [43] 
IVIG is registered internationally and nationally for only a few specific indications (see Table 2.5). At 
the same time, the majority of IVIG use can be attributed to the off-label use with approximately 150 
varied indications documented, as tabulated by Leong et al.[44] (Appendix D). IVIG has had a huge 
impact clinically, especially in the treatment of some rare disorders in the fields of neurology, 
haematology, immunology, nephrology, rheumatology and infectious diseases. The broad spectrum of 
activity as replacement or booster therapy in humans does not preclude its use as adjunct therapy to a 
myriad of disease conditions.[45] 
Table 2.5: Registered/Labelled uses of intravenous immunoglobulin (2014) 
  
MCC (South Africa)[7] FDA (USA)[46] EMA (Europe)[47] 
Replacement therapy in:  
• Primary antibody 
deficiency syndromes 
Primary immunodeficiencies Replacement therapy in: 
• Primary immunodeficiency 
syndromes with impaired antibody 
production. 
Myeloma or chronic 
lymphocytic leukaemia with 
severe 
hypogammaglobulinaemia 




recurrent bacterial infections in 
patients with chronic lymphocytic 
leukaemia (CLL), in whom 
prophylactic antibiotics have failed. 
  Hypogammaglobulinaemia and 
recurrent bacterial infections in 
plateau phase multiple myeloma 
(MM) patients who have failed to 
respond to pneumococcal 
immunisation. 
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Source: Polygam® . South African Electronic Package Inserts. Polygam. Last accessed on 10 August 2014, 
available online from: http://home.intekom.com/pharm/nbi/polygam.html; 
U.S Food and Drug Administration (FDA)-Last accessed 18 October2014, available online from: 
http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/Fractionated
PlasmaProducts/ucm133691.htm;  
European Medicines agency(EMA)Last Accessed 18 October 2014, available online 
from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000388.jsp-
&mid=WC0b01ac0580032ec8. 
Table 2.5: Registered/Labelled uses of intravenous immunoglobulin (2014) cont. 
MCC (South Africa)[7] FDA (USA)[48] EMA (Europe)[49] 
  Hypogammaglobulinaemia in 
patients after allogeneic 
haematopoietic stem cell 
transplantation (HSCT). 
For immunomodulation in: 
• Idiopathic 
Thrombocytopenic 
Purpura (ITP) in children 
and adults. 
• Kawasaki disease. 




• Kawasaki disease 
Immunomodulatory effect in: 
• Primary immune 
thrombocytopenia* (ITP) in 
patients at high risk of bleeding or 
prior to surgery to correct the 
platelet count. 
• GBS 
• Kawasaki disease 
Allogeneic bone marrow 
transplantation 
Allogeneic bone marrow 
transplant 
 
Children with congenital 
AIDS and recurrent 
infections 
Paediatric HIV Children and adolescents with 
congenital AIDS and recurrent 
bacterial infections. 
 Chronic inflammatory 
demyelinating polyneuropathy 
(CIDP). Only the Gamunex® 
brand manufactured by 
Talecris® is approved for 
CIDP in 2008; under the USA 
Orphan Drug law provisions 
 
 Kidney transplant with a high 
antibody recipient or with an 
ABO incompatible donor 
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Internationally, at least 25 different brands of IVIG exist, all not being the generic equivalent of the 
other. Supply of every product varies greatly from country to country. Registration of each product is 
associated with licensed use for specific indications. Tolerability to different generics is a concern in 
countries where various products exist and choices can be made as to which product is most suitable 
for the individual patient. In South Africa and other developing countries this is not so readily 
available. The current competitors to NBI for example have products that are not financially viable as 
yet and can be procured only at a higher cost. However, these products could offer other benefits like 
decreased reconstitution volumes in fluid restricted patients. 
2.1.6 Literature review 
A literature review was conducted to determine if any similar studies have been done in the audit or use 
of IVIG nationally or internationally. The PUBMED, Cochrane and Google Scholar databases were 
scrutinised using the advanced search builder. Articles were excluded based on the following criteria: 
• In any language other than English; 
• Articles older than 1995 as information was outdated; 
• Articles pertaining to specific indications including Sepsis, Kawasaki disease, ITP, GBS and so 
on; 
• Articles relevant to animal studies in the field of veterinary science; 
• Articles based on internet databases requiring voluntary input by IVIG users and 
• Article pertaining only to costs of IVIG. 
Search terms used in builder: 
1.  Search (((intravenous immunoglobulin) OR intravenous immune globulin) OR ivig) AND use 
OR indication; 
2.  Search (((((intravenous immunoglobulin) OR intravenous immune globulin) OR ivig) AND use)) 
AND hospital;  
3.  Search 1+2 AND off-label; 
4.  Search 1+2+3 AND p?ediatric*; 
5.  Search 1+2 AND Guideline* OR protocol* and 
6.  1+2+3+4+5 
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An initial search was conducted using the terms ‘intravenous immunoglobulin’, OR ‘intravenous 
immune globulin’, OR ‘IVIG’, AND ‘use’. The articles (n=123) in PUBMED were scanned and 
abstracts read for relevancy. Search terms were then built as described above. Articles discussing 
general, unlabelled use, adverse effects, new uses, subcutaneous use and articles demonstrating a need 
for a protocol/guideline were selected. Search strings were developed based on the MeSH search as 
described in Figure 2.2 below. The main articles of interest relevant to this study were selected based 
on IVIG use/utilisation/surveillance in a ward, hospital, multihospital or nationwide setting. This 
yielded 15 articles of which two were only available in abstract form. An advanced Google search was 
then conducted to determine any missing gaps in collation of relevant articles. The same search terms 
were used and a further 10 articles were found, three of which were available only in abstract format. 
Finally, a Cochrane database search using the same terms was conducted yielding zero results relevant 
to the topic above, articles and systemic reviews found referred to specific conditions and uses. 
References were checked in the 25 articles found for further resources of interest to the study and a 
further three articles were found. 
Several searches as described above were conducted for particular subjects of interest to the study. For 
example, the paucity of paediatric data made it necessary to exclude the word paediatric and conduct 
searches based on adult information or where no mention was listed. Search strings were subsequently 
built up to refine each search.  
• Search criteria: Search string 1 PUBMED 
• Search string 2 Google Scholar 










Titles read & abstracts scanned for relevance  
Articles read & included in review based on inclusion & exclusion 
criteria 
n=123 n =353 n = 0 
n =15 n =10 n = 0 
n = 25 
References searched for additional resources  
n = 28 
 
Figure 2.2: Literature review search results 
 
Twenty eight articles were found pertaining to IVIG use, utilisation and surveillance in a hospital 
setting, multihospital setting or countrywide (Figure 2.2). Many other articles appeared to be 
applicable, but upon reading some of them it became clear that they lacked pertinent details or did not 
fit the inclusion aspects considered. Articles were rejected for not being applicable to the search 
criteria, only reporting ancillary issues or being specific to a single clinical indication.[50]  Tables 2.6-
2.8 were developed and created from the articles found on IVIG use at the end of this chapter. These 
summarise and categorise the literature found into Table 2.6: Paediatric-related articles on IVIG 
25 
use/utilisation; Table 2.7: Adult Hospital/s and regional IVIG use/utilisation; and Table 2.8: 
Nationwide/Countrywide use/utilisation of IVIG. What follows are some pertinent articles relating to 
the use of IVIG in paediatrics. 
One of the first articles published on IVIG use in a hospital setting was by Frayha et al. [51] in 1997. A 
series of drug use evaluations were conducted in King Faisal Specialist Hospital, Saudi Arabia during a 
two-month period, pre- and post-guideline implementation and training on IVIG use. As an exploratory 
and rudimentary descriptive study, off-label use could only really be compared to other studies from its 
pre-guideline implementation data (36% labelled use of IVIG). However, a very small sample size 
makes this study significantly weaker than others, yet it serves as a basis for future audits in various 
other countries. A key finding of this study suggests the need for a guideline/protocol to control the use 
of IVIG and the effectiveness of instituting a policy for monitoring therapeutic indication. 
Other studies similar to these that looked into the effectiveness of guideline implementation include the 
first known paediatric only audit on IVIG use in a large children’s hospital in Houston Texas in 1998 
by Gurwitch et al. [52] Off-label use was estimated to be 66% of the 164 paediatric patients surveyed 
pre-guideline implementation and subsequently 7.5% after the introduction of the guideline, 
highlighting the imperative need for guidelines in a paediatric hospital setting. It is comparable from a 
pre-guideline perspective to the other older study in Detroit by Gajewski et al. [53] which looked at four 
hospitals, one of which had 34 beds for paediatric patients. Similarly, this prospective study showed an 
off-label use of 66% in the paediatric population, though the Gajewski study suffers from a small 
paediatric sample size (N=107). The main indications for use reported by the Gurwitch study at the 
paediatric facility included primary immunodeficiency disorders, Kawasaki disease, ITP, GBS, bone 
marrow transplantation, Cytomegalovirus disease and Paediatric HIV. 
Darabi et al. [54] later conducted a retrospective study in Massachusetts General Hospital (2006) looking 
at the indications for use among 194 adult patients issued IVIG over a one-year period. Therapeutic 
indications for IVIG were mainly off-label (57%) by FDA classification, similar to the Texas Paediatric 
Study. The main indications for off-label use included chronic neuropathy including chronic 
inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, as were many of the 
other indications reported. It is important to note that at the time the FDA had only approved six 
indications for use, Guillain-Barré syndrome being an off-label use under the FDA registration process 
in the USA. A possible limitation in assessment of indication as reported in the study could include the 
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fact that all requests for IVIG had to be pre-approved by the blood transfusion service physician before 
being issued for use. A hospital guideline was already in place, which could have controlled the data 
collected further and not shown the number of initial requests for IVIG. 
However, many of the uses seen at Massachusetts General Hospital matched that of the guidelines 
developed by the University Hospital Consortium in 1998 on acceptable use of IVIG which differed 
from the strict FDA registration. Very few randomised controlled trials were and are still currently 
available to rationalise this major off-label use although the Cochrane Database is now addressing 
some of the more common off-label uses. Currently, the FDA predicts that approximately 50 to 70% of 
IVIG use can be attributed to off-label use. This suggests an urgent need for specific trials and 
registration for use. [55]  
The use of IVIG in Canada was highest in the period 1998-2006, showing a 115% increase per capita 
and making them the world’s largest users of IVIG during that time.[56] Efforts to control use have 
included many evidence-based guidelines, and protocols in sub-specialties including neurology, 
haematology, and infectious diseases. The National Advisory Committee on Blood and Blood Products 
and the Canadian Blood Services have developed and maintained at least 15 different evidence-based 
guidelines on specific indications and use.[57]  Registries and databases have been created nationwide to 
monitor and survey the IVIG use continuously. To this end, many studies have resulted from this focus 
group, four of which pertain to IVIG indications and usage in various facilities in Canada (Tables 2.7 
and 2.8).  
In 2003, Hanna et al. [58] conducted a retrospective review in ten teaching and community hospitals, 
two of which were paediatric facilities, representing 890 patients. Their results indicated a 38% off-
label use in the paediatric populations as opposed to 53% in adults. This might suggest that off-label 
use could be more widespread in adult populations but is limited by a selection bias in that only two 
paediatric hospitals featured in the study compared to eight adult hospitals. 
The other paediatric study of note by Dashti-Khavidaki et al. [59] included a sample of 43 paediatric 
patients of which 42% received IVIG for off-label indications in an academic children’s hospital in 
Tehran, Iran. As reported in the study and of interest, patients in the registered use group experienced 
significantly greater clinical improvement than those in the off-label or unregistered group. This study 
also reported 45% adverse drug reactions, which is far higher than the other studies reporting on 
adverse drug reactions, namely Gajewski (12%)[51] and Chen (11%)[6] respectively. They attributed it 
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to potential differences in sensitivities to IVIG formulations or nursing negligence. However, it could 
also be attributed to a more focused and detailed reporting of adverse events in such a setting. 
Of direct interest and relevance to this study are two of the latest articles published in 2013 relating to 
IVIG use in paediatrics. The first study in Cairo[60] describes the use of IVIG in an ICU setting of a 
paediatric tertiary hospital between 2008 and 2011. The study resonates with this research study, being 
the only other study conducting research in a resource limited setting of a low to middle-income 
country in Africa. Interestingly, the results indicate conformance with FDA and Level 1a evidence 
(using the American Heart Association framework on levels of evidence) for 62% of the study patients. 
The sample size was limited to 45 patients who received IVIG in an ICU setting, restricting any 
inferences to greater compliance in this setting from being made. In direct contradiction, Wu’s study 
demonstrated interesting outcomes, possibly unique to the environment in Asia. This study is noted for 
the largest sample size (N=1302) in a paediatric study over a 10-year period from 2000-2009, recently 
published on data from Singapore[61]. Key findings from this study showed 75% compliance with FDA 
approved indications for IVIG use, a much larger proportion of patients with Kawasaki disease 
compared to other studies, where non- approved FDA indications like neonatal sepsis and secondary 
immunodeficiency had negative outcomes resulting in mortality of the patients despite IVIG usage. 
Finally, this study demonstrated the need for more studies to investigate the role of IVIG use for these 
indications and the necessity for local guidelines to monitor the prescription of IVIG. Two other studies 
in paediatrics conducted in the United Arab Emirates (UAE) and Italy with relatively small sample 
sizes (N=74 and N=67 respectively), indicate a 61% and 26% off-label use with weak evidence. Tables 
2.6, 2.7 and 2.8 were created by the researcher to summarise all relevant articles relating to IVIG use 
that have been published to date. However some clear distinctions are seen between all the available 
literature relating to IVIG use and indications that must be noted: 
• Differences in definitions of appropriate use, recommended use and inappropriate or off-label 
use across hospitals, boards, regions and countries make extrapolation and comparison difficult 
to quantify. This is particularly relevant as greater knowledge and more technological systems 
for data collection come to the fore. 
• Variances in sample size or inadequate sample sizes. As many of these studies serve as 
exploratory studies in their respective country, initial sample sizes were very small and the 
methodology not described in great detail. Subsequent larger sample sizes in studies tended to 
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focus on either adult and paediatric data, or national databases across various hospitals, states or 
countrywide and relied on existing databases for collection of data.  
• Nine articles mention paediatrics specifically in their summation. However, it cannot be ruled 
out entirely that paediatrics was not a component of larger multihospital and state-wide studies. 
As such, these greater sample sizes could give a more representative view of IVIG use in that 
location but no inferences can be made on paediatric usage. 
• Sources of information. Some articles pose significant limitations depending on the method of 
data collection. These include national databases, folder reviews, clinical case notes, and expert 
opinion. 
• Type of study. Prospective versus retrospective studies often yield very different results. In 
general, a prospective review is a stronger study.  
• Guidelines approved for use. One of the greatest limitations to comparisons between similar 
articles listed in the table is the immense variation in guidelines used in these articles. Whilst 
some studies use the audit to make recommendations towards a need for a guideline, a few 
articles relate directly to the effectiveness of available guidelines. In addition, some articles use 
national guidelines (where available), while others rely on clinical associations like 
haematology, neurology etc. Added to this, some articles use FDA or European Medicines 
Agency (EMA) registration approvals and in-hospital policies where available. Clinical 
expertise and panels are also prevalent in distinguishing recommended and non-recommended 
indications. All this leads to a very subjective and variable record of results that is relevant for 
the specific locations only. Interestingly, the study by Feasby et al. demonstrated how 
ineffective guidelines were in containing the off-label and non-recommended use of IVIG in the 
British Columbian hospitals. 
• Approved and registered indications. Finally, it is quite apparent that the different registrations 
for particular indications make a significant difference in results. Guillain-Barré syndrome for 
example is not approved for use by the FDA and consequent interpretation of off-label use is 
influenced greatly by this fact. In Europe, where Guillain-Barré syndrome was approved for use 
under the EMA, studies conducted there exhibit a generally smaller percentage of off-label use, 
one reason of which could be attributed to this registration. Some countries like Australia and 
Canada where established guidelines exist also include a set of recommended indications that 
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whilst not strictly registered for use, have sufficient evidence showing efficacious and 
appropriate use. This naturally influences the off-label results further. 
• Levels of evidence. In some studies, labelled/off-label uses were not the only criteria considered
as appropriate. Levels of evidence are defined in different studies by different
bodies/organisations. These levels are utilised to categorise the literature available for a
therapeutic indication by the strength of the studies available (evidence-based medicine) but do
not all conform to each other, making direct comparisons between levels difficult.
Nevertheless, by far the majority of studies display an apparent need for consensus guidelines, 
approved definitions and indications with standardised level of grading. Off-label or unregistered use 
varied in the paediatric studies from 25% to 66%, and it is unknown what the paediatric population in 
the South African setting would reflect. To date, whilst many studies have been conducted in high-
income country settings, none exist in South Africa and the picture may be very different for a number 
of reasons. First and foremost, resource limitations and an increased focus by national health budgets 
on highly prevalent diseases may influence the unregistered uses and indications for use. In addition, 
the burden of disease may be different taking into consideration factors like HIV, TB and other 
infectious diseases that this cohort may be exposed to. 
To date no publication exists expounding on the use and development of a national guideline or 
protocol governing use of IVIG within South Africa. The provincial pharmaceutical and therapeutics 
committee of the Western Cape is interested in collating the information presented from this study from 
a paediatric perspective. An adult review on usage will also be undertaken and the indications then 
evaluated for clinical and evidence-based efficacy towards the formulation of a guideline or protocol. 
With clinical research continuously expanding the potential applications of IVIG, this concern is valid. 
The broad mechanism of action allows IVIG as a therapeutically viable choice and often last resort in 
many disease and infectious states. Whilst attempts have been made to document the unregistered uses 
in various institutes internationally, and develop a guideline from which to control usage, no such audit 
has been documented within South Africa. This information could be used to formulate evidence-based 
guidelines and policies regarding the unregistered use of IVIG within the paediatric and South African 
context. 
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sample size Registered Board Guideline/ Guidance for classification
Percentage Labelled Use (by number of 
Patients)Recommended Use and non-
recommended use where  otherwise stated
Percentage Off-labelled Use Adverse Drug Reactions
Gajewski et al. [50] Detroit, U.S.A
Retrospective 
Audit 1994 6 months 107 4 34 patients FDA
FDA categorisation/ available literature/ 
national guideline for categorisation
11% in the adult hospital and 35% in the paediatric 
hospital
89% in the adult hospital  and 65% in the 
paediatric hospital 11.30%
Gurwitch et al .[51] Texas, USA Prospective 1998
12 months-1996-
1997 164 1 164 FDA Hospital IVIG Taskforce Guideline Pre guideline: 44% and Post guideline: 93%
Pre Guideline 66%; Post guideline7.5% Unknown




1014 adults and 
890 paediatric 
patients
10 890 FDA Assessed against the Canadian consensus guidelines for IVIG use in 1997 47% and 62%
53% adults and 38% paediatric 
(appropriate use by guideline) 6% no 
scientific evidence
Unknown
Dashti-Khavidaki et al .[57] Tehran, Iran Prospective 2008 6 months- 43 1 43 FDA Unknown 58.00%
16.7% with scientific evidence and 25% 
without evidence 45.80%
Ruiz-Antorán et al. [3] Spain Prospective 2010
3 months-
2004/2005 554 13 554
 EMA(Spanish 
Medicine Agency) EMA 60%
16% with scientific evidence and 24% 
withut scientific evidence Unknown
Dawoud et al. [62]
United Arab 




1 74 FDA Reuters classification  46% appropriate use in adults,39% appropriate use in paediatrics
54%  inappropriate use in adults and 61% 
inapproprite use in paediatrics
Galal N.M[58] Cairo, Egypt Retrospective 2013 2008-2011 45 1 45 FDA FDA categorisation/Evidence Category 62% with Evidence 1a/1b 38% level 2/3 (weak) evidence
recorded by 
adverse event eg. 
Fever, headache, 
Wu et al .[59] Singapore Retrospective 2013 2000-2009 1302 2 1302 FDA FDA classification 75% 25% 6.50%
De Meo et al .[63] Italy Retrospecitive 2013 2011-2012 67 1 67
EMA(Regional 
guideline) Regional Guideline 74% 26% Unknown
Table 2.6: Summary of articles published on IVIG use in paediatrics




Registered Board Guideline/ Guidance
Percentage Labelled Use (by number of 
Patients)Recommended Use and non-
recommended use where  otherwise stated
Percentage Off-labelled Use (with Scientific 
Evidence and without sc evidence) Adverse Drug Reactions




Follow up Drug Use 
evaulation;pre and post 
guideline
1993 10 months-1994
131 (total Drug 
Use Evaluations 
DUE's)
1 0 FDA PTC- Hospital guideline categorisation Pre Guideline: 36% ; post guideline: 82% Pre guideline: 61% Final DUE post guideline:18% Unknown
Lee  et al. [73]
Auckland, New 
Zealand Retrospective 1998 1996 135 4 Unknown Unknown Autralasian Society of Blood Transfusion Unknown Unknown 13 cases: 10%
Chen et al .[6] USA Prospective 2000 Unknown 251 12 Unknown FDA Consensus guidelines for categorisation 43% 52%: 38% and 14% 11%
Vinent et al .[86] Barcelona, Spain
Prospective-
Retrospective 2001 1998-2000 62 1 0 EMA/ UHC
University HealthSystem Consortium 
Guideline for Off label  Use 
Recommendations/categorisation
70% 19% and 11% 17 times= 27%
Pendergrast et al .[75] Toronto, Canada Retrospective 2005 1995-2000 429 4 0 FDA
FDA,American and Canadian Consensus 
conference >80% (by publsihed recommendations) <20% Unknown
Perayre Badia et 
al .[74]
Barcelona, Spain Prospective 2006 5 years- 2000-2004 405 1 0 Spanish Medicines agency/ EMA
University hospital Consortium Expert Panel 
for Off Label Use 5.00% 24.2% and 8.4% Unknown
Darabi et al .[52]
Massachusetts, 
USA Retrospective Audit 2006 2004 194 1 0 FDA
Pre-approved by a Blood Transfusion Service 
Physician prior to issue *43.4%
*56.6%: authors claim it adheres mostly to 
University hospital consortium guideline due to pre-
approval process.
Unknown
Lin et al. [76] Sydney, Australia Prospective 2006
2003-2004 (6 





AHMAC (Australian Health ministers 
Advisory Council 2000 guideline) 74.50% 25.50% Unknown
Alangari et al. [78] Saudi Arabia Retrospective 2008 3 years: 2003-2005 305 1 0 FDA Unknown 35.70%
9.5%: First line off label indication, 31.8% for 
alternative off-label recommendation and 24.4%: ina 
ppropriate use
Unknown





Retrospective 2009 2003-2006 235 1 0 EMA/FDA No mention of categorisation in study 60.40% 25.6% and 14% Unknown
Frauger et al. [2] Marseille, France Prospective 2010
6 months- 
2005/2006 435 3 1 EMA
CEDIT guideline(Committee for the 
Evaulation of Innovative Technologies) 70% 9% & and 18% Unknown
Foster et al. [82] Canada Retrospective 2010 5 years: 1999-2004 145 5 ICUS 0
FDA/Candian 
Registration
Categorised by National Advisory Committee 
on Blood and Blood Products and Canadian 
Blood Services
18.6% (appropriate) 74.5% potentially indicated and 6.9%, not indicated/inapropriate
199 adverse events but 
causality not established: 
confounding
Farber et al. [84] Belgium Retrospective 2011 1 year: 2009 136 1 0 EMA Unknown
Manna et al [83]
Sasakatoon Health 
Region, Canada Retrospective 2013 2011-2012
2011:227, 
2012:216 1 Unknown Canadian FDA Canadian Regultions/guideline 2011:64%, 2012:79% 2011:36%, 2012: 21% 0
Moralejo et al [85] Spain Retrospective 2014 2012 77 1 Unknown
British clinical 
guideline
British clinical guideline for hospital use: 2nd 
Ed. 2011: colour classification Strong evidence: 44%; Reasonable evidence 34% Weak evidence 22% Unknown
Table 2.7: Summary of articles published on IVIG use in adults
Article City, Country Study Type Year Published Period of study Sample Size Total Number of hospitals
Paediatric hospital/ 
activity Registered Board Guideline/ Guidance
Percentage Labelled Use (by number of 
Patients) Recommended Use and non-
recommended use where  otherwise stated
Percentage Off-labelled Use (with Scientific 
Evidence and without sc evidence)
Adverse Drug 
Reactions
Hutchinson et al. [81]









Regional use in 8 participating 
District Health boards Unknown
Australian Health 
ministers Advisory 
Council Indications for 
IVIG
Australian health ministers Advisory council 
guideline and Auckland district Health board 
guidelines
Varied across regions Varied across regions Unknown
Constantine et al .[5]
Atlantic Provinces, 
Canada Retrospective 2007 2 years unknown Provincial database registry Unknown FDA
Regional guideline, national guidelines/ expert 
opinion/optimization tools 37.1%
62.9% off label. Post guideline strategy: 4.2 % 
decrease in off label Unknown
Simeons, S.[80] Belgium Retrospective 2011 2007 9629
47 hospitals: All hospitals in 
Belgium from IMS Health hospital 
database
Unknown EMA Unknown Estimate 50-60% Estimate 40-50% Unknown
Feasby et al. [77]
British Columbia, 
Canada Retrospective 2012 2001-2003 2256
Electronic database of all facilities 
using IVIG in British Columbia Unknown
Clinical expert panel 
recommendations
Clinical expert panel recommendations and 
adherence to IVIG Management Program 54.1% 17.4% uncertain benefit and 28.% inappropriate Unknown
Table 2.8: Summary of articles published on IVIG use regionally or countrywide
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Polyvalent intravenous immunoglobulin (IVIG) is registered for a limited number of specific 
indications in South Africa but is increasingly being used for un-registered or off label uses.  
No guideline exists nationally to monitor and control IVIG   prescription. This results in its 
use in many clinical situations with varying levels of evidence.  
Objectives and Methods 
This study aimed to ascertain the registered and unregistered use and cost of IVIG at a 
tertiary paediatric hospital in South Africa. 
A cross sectional descriptive study design was employed with a patient folder review, 
supplemented by data from the electronic pharmacy dispensing database, as well as the 
National Health Laboratory Service database, was conducted on all patients (0 to 18 years) 
who were issued IVIG as out- or inpatients during a 39 month period from 2009 to 2012. 
Results 
During the study period, 185 patients received at least one dose of IVIG and a total 916 issues 
(3641.5g) were dispensed.  In 76 (44%) patients (involving 414 issues, 48%), the Medicines 
Control Council registered indications for its use were followed. Only 87 (53%) of the 
patients were tested for HIV and in these the HIV sero-prevalence was 19%. IVIG accounted 
for between 1.6%, 1.7% and 4.6% of the pharmacy expenditure per year in the study period. 
Conclusion 
More than half of all IVIG issued at this paediatric hospital was used off-label. Considering the 
pressures on supply and the pharmaceutical costs, a more standardized, protocol-driven 




Polyvalent Human Intravenous Immunoglobulin (IVIG) has been used to treat several groups 
of conditions including primary immunodeficiencies, secondary immunodeficiencies, 
autoimmune diseases, some neurological disorders and an ever widening array of other 
disease conditions for which there are varying levels of epidemiological evidence for its 
treatment efficacy.[1] Many studies on IVIG focus on its potential benefit in a range of 
different conditions, the ever increasing associated costs and the limited supply due the 
stringent criteria by which the product is manufactured. Several countries including the 
United States of America, United Kingdom, Canada and Australia have published evidence-
informed guidelines for the administration and control of intravenous immunoglobulin 
therapy. [2,3,4]   
In South Africa, IVIG is registered for a narrow spectrum of clinical indications by the 
Medicines Control Council (MCC) (Table 3.1). However, there is little or no clinical 
guidance on the multiple potential additional applications of IVIG use, leading to its 
subjective and indiscriminate usage locally. 
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Table 1: Comparison of registered/labelled indications for IVIG in the USA, Europe and 
South Africa 
MCC (South Africa)* FDA (USA)† EMA (Europe)‡ 
Replacement therapy in:  





Replacement therapy in primary 
immunodeficiency syndromes with 
impaired antibody production. 
Myeloma or chronic lymphocytic 
leukaemia with severe 
hypogammaglobulinaemia and 
recurrent infections 
Chronic lymphocytic leukaemia 
 
Hypogammaglobulinaemia and 
recurrent bacterial infections in patients 
with chronic lymphocytic leukaemia 
(CLL), in whom prophylactic 
antibiotics have failed. 
  Hypogammaglobulinaemia and 
recurrent bacterial infections in plateau 
phase multiple myeloma 
(MM) patients who have failed to 
respond to pneumococcal immunisation. 
  Hypogammaglobulinaemia in patients 
after allogeneic haematopoietic stem 
cell transplantation 
(HSCT). 
For immunomodulation in: 
• Idiopathic Thrombocytopenic 
Purpura (ITP) in children and 
adults. 
• Kawasaki disease. 
• Guillain-Barré Syndrome. 
• Idiopathic thrombocytopenic 
purpurae 
• Kawasaki disease 
Immunomodulatory effect in: 
• Primary immune thrombocytopenia 
(ITP) in patients at high risk of 
bleeding or prior to surgery to 
correct the platelet count 
• Guillain Barré Syndrome (GBS) 
• Kawasaki disease 
Allogeneic bone marrow 
transplantation. 
Allogeneic bone marrow 
transplant 
 
Children with congenital AIDS 
and recurrent infections 
Paediatric HIV Children and adolescents with 
congenital AIDS and recurrent bacterial 
infections. 




 Kidney transplant with a high 
antibody recipient or with an 





In South Africa, IVIG is procured primarily through the National Bioproducts Institute (NBI), 
the commercial unit of the South African Blood Transfusion Services. It is obtained from 
pooling the plasma of multiple non-remunerated blood donors, [5] where these IgG molecules 
Source: * Polygam® . South African Electronic Package Inserts. Polygam. Last accessed on 10 August 2014, 
available online from: http://home.intekom.com/pharm/nbi/polygam.html 
†U.S Food and Drug Administration (FDA)-Last accessed 18 October2014, available online from: 
http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/Fr
actionatedPlasmaProducts/ucm133691.htm 




                                                          
reflect the collective acquired immunity of the donor pool from which it is derived. Hence, 
like blood and other blood derived products, it is regarded as a scarce commodity, as its 
supply is restricted by the availability of safe and excess donor serum. In addition, IVIG is 
expensive: gram for gram it is currently more expensive than gold.§ Commercially there are 
over 25 licensed IVIG products available worldwide but the therapeutic efficacy of each unit 
varies depending on the concentrations of constituent immunoglobulins, the excipients added, 
the manufacturing process and the osmolality, pH and dextrose content of the final product. 
Consequently different preparations of IVIG are not strictly generics of each other.  
This study describes the use (registered or non-registered) and cost of IVIG in the paediatric 
practice of a public sector hospital in South Africa. 
RCWMCH in Cape Town is the paediatric academic referral hospital in the Western Cape. 
About 250 000 in- and outpatients are seen per year, with patients being referred from other 
parts of the country, as well as specialist referrals from the rest of Africa.[6]   
Methods 
This health systems research used an observational, cross-sectional descriptive study design. 
The study sample was made up of all paediatric patients (0 to 18 years) who were issued 
polyclonal IVIG both as in- and outpatients during a 39 month period from 2009 to 2012. 
Any child receiving intramuscular immunoglobulin was excluded in the study.  
Data was collected from the pharmacy’s electronic dispensing database, supplemented by a 
folder review of all patients who had IVIG dispensed. Four attempts were made to obtain 
patient folders if they were not found initially. All extracted data was recorded on a 
customised data-collection sheet by a trained fieldworker. An ‘issue’ was defined as a dose of 
IVIG dispensed in any of its varied strengths and recorded against a patient name in the 
dispensing database of the pharmacy. Patient level data was anonymised. The study received 
bioethics approval (BE0071/12) from the University of KwaZulu-Natal, as well as hospital 
permission. 
§  Incidentally, it is interesting to note that the gold price per gram ranged from around ZAR 250. 
(2009) to ZAR 420. in this time period of the study. Currently the gold price per gram is ZAR 416. 




                                                          
Diagnoses leading to the prescription of IVIG were obtained from the patient folders and the 
primary indications were verified by the responsible clinical department. Patients were 
categorised as being given IVIG for registered use if diagnosed with one of the seven MCC 
registered indications. All other indications were categorised as unregistered (off-label) use.  
Additional data such as results of liver function tests, blood counts, Immunoglobulin G (IGG) 
trough testing and HIV status were obtained from the National Health Laboratory Services 
(NHLS) data-base at the hospital. Where relevant, data was described with a 95% confidence 
interval utilising a p=0.5 error margin. 
Financial data was obtained from 2 separate sources: 1) patient level data was collected from 
the dispensing system in the pharmacy; 2) Financial data was extracted from the hospital 
information system. Hence the financial trends for IVIG use could be reported from 2009 to 
2014. The patient review which was from 2009 to 2012. Annual expenditure on IVIG was 
adjusted to 2014 values using the South-African consumer price index and hence represents 
real values in order to make the data stationary.  
Results 
A total of 185 patients received IVIG in the study period, of which 100 (54%) were males. 
There were 45 (24%) issues to infants, 73 (39%) to children one to five years of age and 67 
(36%) to those between five and 18 years of age. The median and mean ages of paediatric 
patients who received IVIG were 3.4 and 5.0 years respectively. A total of 916 issues of IVIG 
were made to 185 patients during the study period. Patient data on duration of therapy for 185 
patients included 135 (73%) patients who were given a once off dose, 36 (20%) received 
IVIG therapy on two successive days and 13 (7%) of patients received three to nine 
successive doses of IVIG. One patient was issued 14 successive days of IVIG therapy.  Two 
patients following liver transplant received 50 and 54 doses of IVIG respectively. Most (154, 
90%) of the patients received IVIG for the first time in the study period.  
Only 28 (15%) of 185 patients, were tested for IGG trough levels of which seven had primary 
immunodeficiency and five had cancer. Only eight of 171 (4%) patients had a record of 
having had adverse events due to administration of IVIG. Liver function tests used to assess 
the effect of IVIG on liver enzymes were reported in 57 (31%) of the patients. 
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Only 87 (47%) patients had their HIV status recorded of which 17 were HIV infected giving 
an HIV sero-prevalence of 19.5% (95% Confidence Interval (CI): 11.2% to 27.9%). The rest 
were either not HIV tested or no results were found.   
Table 2: Paediatric patient demographics who were given IVIG at RCWMH in the study period 
 Age < 1 year Age 1 to < 5 years Age ≥ 5 years Totals 
Number of patients (%) 45 (24%) 73 (40%) 67 (36%) 185 
Number of issues 132 468 316 916 
Males n (%) 25 (56%) 37 (51%) 38 (57%) 100 (54%) 
Mean weight (kg) 6.3kg (n=41) 12.8kg (n=67) 28.9kg (n=61) 17.0kg (n=169) 
Mean dose prescribed (g) 8.7 20.2 29.1 21.6  
Mean concentration (g/kg) 0.86 0.81 0.77 0.81 
HIV tested† (%) 27 (31%) 36 (41%) 24 (28%) 87 (47%) 
HIV +ve n (%) 8 (30%) 3 (8%) 6 (30%) 17 (19%) 
Registered Use * n (%) 16/41 (39%) 43/68 (63%) 17/62 (27%) 76/171 (44%) 
*Diagnosis available on 171 /185 patients †PCR and/or Rapid testing 
Table 3: Clinical categories of patients in study by age group and issues of IVIG 
Clinical Categories Age < 1 Age 1 -<5 Age  ≥ 5 Patients  n (%)** 
Issues  
n (%) 
Primary Immunodeficiency ‡ 3 4 2 9 (5%) 215 (25%) 
Guillain-Barré syndrome ‡ 1 22 8 31 (18%) 98 (11%) 
Kawasaki's Disease ‡ 6 11 2 19 (11%) 46 (5%) 
Chronic Lymphocytic 
Leukaemia ‡ 
0 2 1 3 (2%) 19 (2%) 
Paediatric HIV ‡ 4 1 1 6 (4%) 16 (2%) 
Idiopathic Thrombocytopenic 
Purpura ‡ 
















8 (1%)  













Other oncology 0 4 2 6 (4%) 73 (8%) 
other autoimmune disorder 1 2 6 9 (5%) 63 (7%) 
Other infections 11 4 7 22 (13%) 50 (6%) 
Kidney transplant 0 2 6 8 (5%) 28 (3%) 



















Sub-total off-label use 25 25 45 95 (56%) 458 (53%) 
Total  41(24%)   68 (40%) 62 (36%) 171(100%) 872(100%) 
‡ MCC registered indications 
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The clinical indications for having received IVIG were identified from the folders in 171 
(92%) of the 185 paediatric patients in the study sample, which accounted for 872 IVIG 
issues (Table 3).Only 76 (44%) of the patients issued IVIG had diagnoses that were for 
registered indications as per MCC (Table 2). This accounted for 414 (47%) of the 872 total 
IVIG issues during the study period. This varied according to age group: registered use was 
highest (57%) in patients in the one to five year category and lowest (21%) in patients less 
than one year of age. A further 14 patients with 21 issues had indications for which IVIG 
could not be verified by the relevant clinicians and had to be labelled ‘uncertain’. The total 
grams administered in the study period were 3641.5g and the mean dose prescribed for a 
registered indication was 22.6g compared to 19.7g for unregistered indications.   
 
Table 4: Categorisation of unregistered diagnoses in this study (n= 94) by patient 
numbers 
 Category Named conditions 
1 Other Infections  sepsis (17), encephalitis(5) 
2 Other Autoimmune 
disorders 
systemic lupus erythematosis (3), dermatomyositis (4), systemic juvenile 
idiopathic arthritis (1), Evan’s syndrome (1) 
3 Other Haematology haemophagocytic lymphohistiocytosis (2), chronic anaemia secondary to 
parvovirus (1) 
4 Other Neurological 
conditions 
peripheral neuropathy (1), transverse myelitis (1), acute demyelinating 
encephalomyelitis (1), radiculomyelitis (1), acute inflammatory 
demyelinating polyneuropathy (1), Sydenham’s chorea (1), 
neurodegeneration (2), opsoclonus-myoclonus-ataxia syndrome (1), 
myoclonus(1) 
5 Other Oncology acute lymphocytic leukaemia (4), juvenile myelomonocytic leukaemia (2) 
6 Other Transplants liver transplants (16), stem cell (1), solid organ (1) 
7 Thrombocytopaenia acute thrombocytopaenia (4) 
8 Kidney Transplant acute renal rejection (5), antibody mediated rejection (2), Takayasu 
arteritis failed transplant (1), prevention of rejection (1) 
9. Uncertain generalised muscle weakness (1) 
large ventricular septal defect  (1) 
type 1 truncus arteriosus (1) 
bronchopneumonia (1) 
tracheostomy for glial heterotopia (1) 
asymptomatic anaemia (1) 
lobular panniculitis(1) 
profound anaemia: recurrent episodes(1) 
BCG disease(1) 
acyanotic heart disease(1) 
Hirschsprung's disease(1) 
lymphadenopathy(1) 




The total cost of all IVIG in the study period was ZAR 2.9 million, of which ZAR 1.7 million 
was spent for unregistered indications. The cost per patient amounted to ZAR15 937. The 
highest IVIG issue-values were for Guillain-Barré Syndrome (GBS) (ZAR 301 586), primary 
immunodeficiencies (ZAR 340 953) and ‘other transplants’ (ZAR 546 708). The mean issue 
value per patient in this subset (unregistered) was ZAR 3 732 as opposed to the registered use 
of ZAR 2 653 in 2014 values. 
IVIG comprised 1.6% of the total annual pharmacy expenditure in 2009/2010, 1.7% in 
2010/2011 and 4.6% in 2011/2012 financial years respectively and accounted for ZAR 24 
294, ZAR 24 847 and ZAR 60 251 per 1000 admissions in those respective financial years. 
Figure 1 demonstrates the mean monthly and annual IVIG expenditure by financial year. The 
general trend shows an increase in real expenditure on IVIG, both in real terms and as a share 
of RCWMCH pharmacy budget, except for the 2013/14 financial year. 
 
Figure 1: Expenditure on IVIG against Percentage of Pharmacy expenditure adjusted 





























2008/ 2009 2009/ 2010 2010/ 2011 2011/ 2012 2012/ 2013 2013/ 2014
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Discussion 
Intravenous immunoglobulin use has been reported in 28 studies in a wide range of settings 
both in adults and children in an attempt to rationalise usage or formulate guidelines for 
controlling it. To date, no study on IVIG usage and its indications has been reported in South 
Africa. When considering registered and unregistered uses, there was a disparity between the 
number of patients (185) prescribed IVIG and the number of issues per patient. In addition, 
some patients were prescribed a disproportionate number of issues. 
There are currently differences in registered indications between the United States Food and 
Drug Administration (FDA), European Medicines Agency (EMA) and MCC (Table 1). The 
major difference is that in the US, IVIG is not registered for use in GBS as plasmapheresis is 
considered the therapeutic modality of choice and has a better cost-benefit ration than IVIG 
use.[7]  
In 2013, a study of 45 patients in Cairo, Egypt [8], described the pattern and usage of IVIG in 
a paediatric intensive care facility. In this resource-limited setting, (24, 62%) of IVIG use was 
for non-registered indications but where there was ‘a high level of evidence’. Neonatal sepsis 
was categorised as having a high level of evidence and was the main indication for IVIG use. 
Recent studies suggest that neonatal use in sepsis may only be beneficial prophylactically 
where resources permit usage. [9] The use of IVIG for sepsis in our study (17, 10%) was 
considered as ‘unregistered’ by the MCC, however only four (2%) of our patients, could be 
classified as neonates.  
Other paediatric studies on IVIG use in the US (Texas),[10] Iran (Tehran),[11] Spain,[12] 
UAE[13] and Asia (Singapore)[14], represent a large range of  clinical care and socio-economic 
background, showed a variety of unregistered/off label use, in 25% to 66% of instances. 
Some reports quantify registered uses of IVIG, whereas other studies describe the evidence-
base for IVIG use. Comparing the evidence is further hindered by the different policies 
followed by registration bodies, the definition of appropriate use, various guidelines utilised 
as well as different classifications of evidence used. Most of the reported studies used the 
FDA classification to determine on/off label usage, thus excluding GBS. The exception was a 
Spanish study which used the EMA guidelines in it classification of off-label use. 
Interestingly, the Asia study showed greater compliance to FDA approved indications, 
compared to the other studies. Most use in this study was for patients diagnosed with 
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Kawasaki’s Disease (794, 60%) receiving IVIG, which reflects the higher burden of this 
disease in Asia. [14]  
Our results show more off-label / unregistered IVIG use both by patient numbers and by 
IVIG issues compared to other paediatric studies reported. Only the UAE study (N=74) 
reported 61% off label use by FDA criteria, but was limited by a small sample size. 
Obtaining a primary diagnosis was a challenge in patients with multiple co-morbidities, as the 
data was retrospectively extracted from the patient medical records. Legibility of the notes 
was low and detailed diagnosis and treatments were often absent. The dose of IVIG 
prescribed was mostly evidence-based for specific indications but the length of therapy given 
varied greatly. ICD10 codes were not recorded by clinicians. The consultants responsible for 
the original care of the patients were asked to verify probable reasons for using  
Most IVIG for unregistered use was prescribed for ‘other transplants’ (189 issues to 18 
patients), predominantly for liver transplants and mostly daily IVIG was prescribed for a 
minimum of one week (Table 3,4). IGG trough testing was one of the variables considered in 
the study as a marker for determining the effectiveness of therapy and the need for further 
IVIG.  Only two patients with liver transplant were screened for IGG trough testing and none 
during the course of IVIG therapy. The use of IVIG post liver transplantation though 
becoming more common, is not yet standard level of care.[15] A more uniform basis for IVIG 
use will need to be explored thoroughly in further trials. 
Nine patients with 215 issues were classified as having a primary immunodeficiency and all 
were assessed with IGG trough testing and IGG levels taken for outcome post IVIG 
treatment. Monthly doses of IVIG were issued in line with dosing practises. A further six 
patients had paediatric HIV with associated infections. It is important to note that data in this 
study showed that only 47% (87 / 185) had evidence of HIV PCR or Rapid testing, judging 
both by the NHLS database and clinical notes. This is perturbing considering that children 
with congenital HIV and recurrent infections are a registered indication for IVIG therapy. In 
addition, South Africa is in the midst of a national drive to increase detection and treatment 
of HIV. This would suggest that insufficient testing for HIV (Rapid and/or PCR) was either 
offered or recorded in this paediatric facility. 
A further 14 (8%) patients had uncertain indications for being prescribed IVIG or may be 
considered as in the case of the Cairo study used  because no other therapeutic option was 
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available, lack of a suitable alternative or needing an urgent response (Table 4). The disease 
ranges in these patients were varied, no trends other than stat doses could be found and 6 of 
these patients were issued IVIG whilst in the intensive care unit. IVIG could have been 
administered as ‘last chance medicine’ in acutely ill patients in a last ditch effort to improve 
outcome. Apart from the registered clinical categories, the unregistered ones listed as 
diagnoses needed to be evaluated for evidence and a clinical recommendation made for use in 
various conditions approved by the Provincial Pharmaceutics and Therapeutics committee. 
There are varying levels of evidence available for potential use of IVIG. Within a resource 
constrained setting the thorough evaluation of the evidence-base and a clinical guide to use 
should be the natural next step. 
As compared to most other studies in paediatric IVIG use, which were limited by short 
review times, small sample sizes and /or restricted to specialised care, this study covered 39 
months of continued usage within a whole hospital. It is important to note that this study was 
limited to describing clinical use by MCC registration status. The analysis of the evidence-
base for each unregistered indication was beyond the scope of the study. Expenditure on 
IVIG by year appears to be increasing with a slight decline in the 2013-2014 financial years 
possibly due to very few transplants taking place that year. Now that it is evident that the 
majority of use is unregistered and seeing that IVIG is a costly therapeutic option, it becomes 
imperative to establish the evidence-base for use when designing a guideline/ protocol for the 
paediatric use of IVIG.  
Limitations to study 
There were two significant sets of information bias arising from (a) the use of the pharmacy 
dispensing database system (b) the interpretation of the diagnoses by the investigator. In the 
former, all pharmacists will at some time or other have issued IVIG via the pharmacy 
dispensing system, so that the electronic record reflects the average accuracies/ inaccuracies 
of all the staff over the past three years. In the latter, the investigator will have had to 
interpret a number of usually clinician-specific diagnoses and allocate them to a diagnostic 
category. Most clinical notes do not list all diagnoses, let alone the primary diagnosis, so that 
it may not have been clear which indication IVIG was prescribed for in the first instance. Due 
to this, it was not possible to apply International Classification of Diseases (ICD) 10 
diagnostic labels in all cases. The ability to retrieve all the folders and verify the electronic 
database was also not possible in all cases. 
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Conclusion and Recommendations  
The majority of IVIG used in this paediatric referral hospital in South Africa was for 
unregistered indications in the study period.  Ascertaining the diagnosis and indications for 
IVIG use retrospectively from patient records was a challenge because of the poor quality of 
recorded patient data. A multihospital study where the indications and issues for IVIG are 
prospectively recorded will reduce information bias and make the findings more 
generalizable. In addition, the list of indications for use presented here would need to be 
categorised and validated for evidence and a clinical guideline developed to manage the use 
within this resource limited setting. It would be recommended that a guideline restricting use 
in unproven indications should be developed in light of product shortages nationally, 
increasing expenditure on the medicines budget, as well as rationalising medicine use 
internally.  
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CHAPTER IV: 
ADDITIONAL RESULTS, DISCUSSION, LIMITATIONS, 
CONCLUSION AND RECOMMENDATIONS 
4.1 ADDITIONAL RESULTS 
The article presented in Chapter III was limited to a 3 000 word count. Even though the article 
answered the aims and objectives outlined in the protocol, Chapter IV presents some of the most 
pertinent additional information obtained in this medical folder review. 
4.1.1 Annual issues of IVIG and grams dispensed 
A total of 185 patients received 3641.5g of IVIG in the study period. Of these issues, 172 (92%) were 
to in-patients admitted to the facility. As this was a paediatric hospital, dosing is based on g/kg and 
small amounts can be attributed to the small patient weights as opposed to those used in adults. The 
usual dose for IVIG as per Polygam® package insert dosing guideline8 is indicated below and serves 
merely as a guide to clinicians prescribing IVIG: 
Replacement therapy in immunodeficiency: 
• Primary immunodeficiency: Starting dose: 0,4-0,8 g/kg, thereafter: 0,2-0,8 g/kg every two to
four weeks to obtain IgG trough levels of at least 4-6 g/L
• Secondary immunodeficiency: 0,2-0,4 g/kg every three to four weeks to obtain IgG through
levels of at least 4-6 g/L
• Children with AIDS: 0,2-0,4 g/kg every three to four weeks.
Immunomodulation: 
• Idiopathic Thrombocytopenic Purpura: 0,8–1 g/kg on day one, may be repeated once within
three days or 0,4 g/kg/day for two to five days. May be repeated if relapse occurs
• Kawasaki disease: 2 g/kg as a single dose in conjunction with aspirin or 1,6–2 g/kg in divided
doses for two to five days in conjunction with aspirin
• Guillain-Barré syndrome: 0,4 g/kg/day for three to seven days.
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Allogeneic bone marrow transplantation: 
• Treatment of infections and prophylaxis of graft versus host disease: 
Starting dose: 0,5 g/kg every week starting seven days before transplantation and up to three 
months after transplantation. 
 





















1g 83 83g 66 66g 52 52g 24 24g  
3g 116 348g 79 237g 88 264g 37 111g  
6g 104 624g 76 456g 56 336g 38 228g  
2.5g 0 0g 1 2.5g 36 90g 0 0g  
12g 0 0g 3 36g 36 432g 21 252g  
Total 303 1055g 225  797.5g 268 1174g 120 615g 3641.5g 
** Data for the first three months issues in 2012 
†† Data for the first three months grams usage in 2012 
 
From Chapter III it is interesting to note that 468 doses (over half of the total issues in the study period) 
were issued to the age group category 1 to <5 years of age. This age group had a mean weight of 
12.8kg. The sharp increase in IVIG usage from 2010 to 2011, as demonstrated in Figure 2.1 of the 
article, is mirrored by weights dispensed (see Table 4.1): Usage rises sharply from 797.5g in 2010 to 
1174g in 2011. The trend appears to continue into the next financial year 2012/2013. Intraglobin F had 
to be used when National Bioproducts Institute experienced major shortages and was unable to meet 





                                                 
South Africa’ via a Section 21 process involving the MCC. As Intraglobin F is only available as a 2.5g 
vial, that can account for variation of the eventual dispensed versus used doses. In most instances 
prescribers use grams closest to the nearest pack size due to the range in dosing available for most 
indications. 
4.1.2 Costing 













% of total 
pharmacy 
expenditure 
2009/ 2010 471 663.71 7.26%  576 709.00 28 727 119.59 1.64% 
2010/ 2011 466 717.02 4.10%  548 185.04 27 124 414.98 1.72% 
2011/ 2012 1 214 928.47 5.01%  1 358 919.06 26 264 778.71 4.63% 
2012/ 2013  1 543 799.36 5.75%  1 632 876.58 28 166 689.00 5.48% 
2013/ 2014  960 287.84 5.77%  960 287.84 25 062 314.00 3.83% 
 
Table 4.2 demonstrates the mean monthly and annual IVIG expenditure by financial year. This 
expenditure is shown in both nominal and real 2014 terms. The real values are the nominal values 
inflated by the applicable South African consumer price index, allowing for direct comparison. The 
figures reflect an increase in real expenditure on IVIG, both in absolute terms, as well as the increasing 
share of the RCWMCH pharmacy budget. Only the 2013/14 financial year shows a drop to pre-2012 
values. Factors influencing this last decrease could have been the reduced number of transplants 
performed in that financial year, as transplants accounted for an ever-increasing share of the increase.  
Cost per patient in this research study sample for the study period amounted to ZAR15 937 for IVIG 
and excludes administration, admission and other associated medication and hospital costs. In 
contradiction, the mean hospital cost per patient for RCWMCH in 2009/2010 was: ZAR2 617; 
2010/2011: ZAR3 090 and 2011/2012: ZAR3 763 respectively and thus considerably lower than the 
cost per patient in this research study sample. 
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of stay (days) 
2009/ 2010 88 949 23 210 153.25 4.8 
2010/ 2011 87 871 22 380 148.81 4.9 
2011/ 2012 83 295 22 551 139.76 4.6 
2012/ 2013 79 061 20 509 133.56 4.8 
2013/ 2014 79 964 22 131 135.60 4.5 
 
Overall there were fewer in-patients and admissions at RCWMCH from 2009 to 2014 (Table 4.3). 
Patient day expenditure and average length of stay are on the wane too. With the opening of 
Khayelitsha District Hospital (April 2012) and Mitchell’s Plain Hospital (Oct/Nov 2013), primary and 
secondary level paediatric patients started accessing the services in their districts, thereby resulting in 
lower admission rates and decreased number of inpatients at RCWMCH, as exhibited. In the past these 
patients would have gone to RCWMCH. In spite of this, IVIG comprised 1.6% of the total annual 
pharmacy expenditure in 2009/2010, 1.7% in 2010/2011 and 4.6% in 2011/2012 financial years 
respectively and accounted for ZAR24 294, ZAR24 847 and ZAR60 251 per 1 000 admissions in those 









Table 4.4: Clinical categories by number of issues, mean issue value and cost (ZAR) in nominal 
values 
Clinical categories 





Other transplantation 2 893 189 546 708 
Primary immunodeficiency 1 586 215 340 953 
Guillain-Barré syndrome 3 077 98 301 586 
Other autoimmune disorders 4 679 63 294 749 
Other infections 3 892 50 194 621 
Kawasaki disease 3 172 46 145 898 
Kidney transplant 4 166 28 116 651 
Other oncology 1 442 73 105 272 
Other neurological conditions 4 666 21 97 996 
Idiopathic Thrombocytopaenia 
Purpura 3 905 12 46 854 
Uncertain 1 792 21 37 626 
Paediatric HIV 1 947 16 31 156 
Chronic Lymphocytic Leukaemia 1 322 19 25 126 
Allogenic bone marrow transplant 2 298 8 18 381 
Other haematology 1 710 5 8 548 
Thrombocytopaenia 993 8 7 944 
All Grps 2 661 872 2 320 071 
 
Table 4.4 describes the comprehensive list of clinical categories by cost, issues and mean issue value 
from most costly clinical category to least costly. The article in Chapter III separates these categories 
by age, patient number and issues by registered and unregistered use. Only the top three most costly 
indications are described in the article due to word limitations so the comprehensive list above allows a 
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clearer picture of the cost drivers of IVIG in the study period by including the mean cost value per 
clinical category. 
4.2 ADDITIONAL DISCUSSION 
[For sense of flow and continuity, the unabridged version of the discussion follows.] 
Approximately 28 studies have looked at IVIG use within different contexts and applications: either 
within a sub-specialty or at facility level; across single facilities or countrywide use; both in adults and 
paediatrics. These studies attempt to rationalise usage or formulate guidelines for controlling use. 
Tables 2.6 to 2.8 (Chapter II) summarise all the pertinent literature. The paediatric study of this 
research study looked at all IVIG issues within a paediatric facility as a whole and was not limited to a 
specific clinical setting such as intensive care or oncology. In specialised units, prescribing patterns 
tend to be affected by the specific conditions seen and can be determined by the failure to achieve a 
desirable response with other agents, lack of a suitable alternative and/or the need for an urgent 
response.  
When considering registered and unregistered uses, the results varied by number of issues as opposed 
to the number of patients in the study sample. Different studies have utilised various methodologies for 
describing use. This study attempted to incorporate three different ways of describing this use: 
• Number of issues: Here the number of issues based on the data recorded in the pharmacy 
dispensing system is reported on. This method allows all the records in the pharmacy displaying 
dispensing records of IVIG to be collated, so it is more comprehensive. However, it is limited 
by the ability to find the folders of these patients in the records department. Furthermore, the 
prescription charts in the folders verified administration of the IVIG. The implication of 
counting the number of issues is that quantities and strengths of IVIG are not incorporated into 
these values and issues represent whole vials rather than final dosage administered.  
• Gram dispensed/used: This data could not be automatically retrieved from the dispensing 
system in the pharmacy as only amounts rounded off to the nearest pack size would have been 
recorded and not the actual dose given. However, to prevent wastage and for convenient dosing, 
most prescribers would use the nearest pack size in their dosing estimations seeing as there is a 
range in doses one could use for specific indications. This was verified by viewing the 
prescription records in each patient folder where obtainable. 
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• Patient numbers receiving IVIG: When determining the use of IVIG by indication and 
consequent registered/unregistered use, it is imperative to describe IVIG use by patient 
numbers. These results give one an indication of the use by the study sample population. Most 
of the IVIG study methodologies use this system. However, this number can be misleading, as it 
does not show the quantity of use/issues/grams utilised stratified by specific indication.  
This study did all three and as such had differing values by grams, issues and patient numbers. 
Reporting by issues could be verified by grams prescribed in the prescription and wastage of IVIG 
could be determined. Interesting concepts arose from this delineation, e.g. primary immunodeficiency 
was determined as being one of the more costly indications yet only nine patients were seen with this 
diagnosis in the study period. This could be ascribed to the extended duration of therapy required for 
this subset of patients. Consequently two trends of IVIG use were distinct: acute versus chronic use. 
Ultimately all three methods displayed an increase in usage and a higher amount of unregistered use. 
4.2.1 Paediatric studies on IVIG (Table 2.6) 
A recent study by Galal[60] described the pattern and usage of IVIG in an intensive care paediatric 
facility in Cairo, Egypt. Sixty-two percent (n=45) of all IVIG use in this resource-limited setting was 
categorised as having level 1a/1b evidence, equivalent to MCC registered use, with 46% (n=21) of the 
cases classifiable as unregistered. This is less to that shown in this research study, in which 56% of the 
issues were for unregistered use by patient numbers. One major difference between the Egypt study and 
this research study was that neonatal sepsis was analysed as having Class 1a evidence. All clinical 
indications for IVIG in sepsis (n=17) were defined by this research study as belonging to the 
unregistered category (MCC) of which four patients could be classified as neonates. A recent 
systematic review and meta-analysis that quoted a low risk of bias of the included studies suggests that 
there is no reduction in mortality in patients with sepsis (RR 0.97; 95% CI 0.81–1.1).[63]  IVIG use in 
neonatal sepsis could be considered only as a replacement to improve outcomes prior to sepsis as 
quoted by this study.[63] 
Other paediatric studies on IVIG use in the USA (Texas)[50], Iran (Tehran)[57], Spain[3], UAE[64], 
Italy[65] and Asia (Singapore)[61] (see Table 2.6) representing a large variation in clinical care and socio-
economic background, show a range of unregistered/off-label use, varying from 25% to 66%. No 
overarching trends are evident. However, a clear distinction is made in trying to elucidate studies that 
quantify registered uses versus studies that seek to delineate the evidence-base of such use. 
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Comparisons are further hindered by variations in the registration bodies, the definition of appropriate 
use, various guidelines utilised as well as different classifications of evidence used as described in the 
in-depth literature review. In addition, most of these studies used the FDA classification to determine 
on/off -label usage, thus excluding GBS. The only exception is the Spanish study[3] which used the 
EMA registration in it classification of off-label use. Interestingly, the Asia study[61] showed greater 
compliance to FDA approved indications, contrary to the other studies with the key feature being a 
remarkably high prevalence of patients diagnosed with Kawasaki disease (794, 60%) receiving IVIG. 
This has been rationalised as representing the higher burden of this disease within the Asian 
population.[61]  
4.2.2 Top three cost drivers of IVIG at RCWMCH in study period 
Most IVIG for unregistered use was prescribed for ‘other transplants’ (189 issues to18 patients), this 
subset being made up predominantly by liver transplants, with all patients being issued daily doses of 
IVIG for a minimum of one week. Alternate day dosing was also evident in one patient for up to seven 
days. Two other patients had recorded use beyond this time. IGG trough testing was one of the 
variables considered in the study as a marker for determining the effectiveness and need for further 
IVIG and determined through laboratory results. Two of these liver transplant patient were screened 
with IGG trough testing pre-therapy and none during the course of IVIG therapy. The prescribing 
patterns by individual clinicians suggest that, based on the evidence available, the use of IVIG post 
liver transplantation though becoming more common, is not yet standardised.[66] A more standardised 
basis for use will need to be explored thoroughly in further trials. 
Nine patients with 215 issues were classified as having a primary immunodeficiency and all were 
assessed with IGG trough testing and IGG levels taken for outcome post IVIG treatment. Monthly 
doses of IVIG were issued in line with dosing practises. A further six patients had paediatric HIV with 
associated infections. It is important to note that data in this study showed that only 47% (87/185) had 
evidence of HIV PCR or rapid testing, judging both by the NHLS database and clinical notes. This is 
perturbing when considering that children with congenital HIV and recurrent infections are a registered 
indication for IVIG therapy. In addition, South Africa is in the midst of a national drive to increase 
detection and treatment of HIV. This would suggest that insufficient testing for HIV (rapid and/or 
PCR) was either offered or recorded in this paediatric facility, the latter being a realistic assumption if 
looking at the quality of the medical notes. 
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It is important to note the differences in IVIG registration between FDA, EMA and MCC. The FDA 
labelled use differs from the MCC in one important therapeutic indication for IVIG: GBS is not 
considered a registered use in the USA. Plasmapharesis is considered a viable treatment modality of 
choice and has a better cost benefit ratio compared to IVIG use in the USA.[67]  GBS was the third most 
expensive indication but had the most number of patients diagnosed with this condition (n=33). 
Consequently, the mean issue value was ZAR3 077. The cost per patient in this subset was much less 
for GBS than for other indications, implying that treating many patients with GBS is more cost 
effective than IVIG therapy for other indications. 
Interestingly mean issue value was highest for other autoimmune disorders and other neurological 
disorders. Indications for use in patients (n) include the following: 
Other autoimmune 
disorders 
systemic lupus erythematosis (3), dermatomyositis (4), systemic 
juvenile idiopathic arthritis (1), Evan’s syndrome(1) 
Other neurological 
conditions 
peripheral neuropathy (1), transverse myelitis (1), acute demyelinating 
encephalomyelitis (1), radiculomyelitis (1), acute inflammatory 
demyelinating polyneuropathy (1), Sydenham’s chorea (1), 
neurodegeneration (2), opsoclonus-myoclonus-ataxia syndrome (1), 
myoclonus(1) 
 
This indicates that very specific conditions under autoimmune and neurological conditions can be 
major cost drivers due to extended duration of therapy. As these conditions are rare diseases with a few 
patients affected each year, evidence-based guidelines may be difficult to develop. At the same time, it 
is exactly in these conditions where the need for scientific justification of use may be highest. 
The results in this research study demonstrate a significantly greater trend towards off-
label/unregistered use both by patient numbers and by IVIG issues compared to most paediatric studies 
cited. This is echoed by the UAE study (n=74) which showed 61% off-label use by FDA but was 
limited by a smaller paediatric sample size and did not provide all clinical paediatric services within its 
facility. The current research study has the advantage of demonstrating use in all clinical areas since all 
paediatric services are offered by RCWMCH. In addition, it highlights the scenario of IVIG use in 
paediatrics in a low to middle-income setting as described. 
Outcome measures, side effects and adverse effects were inadequately described in the doctor’s notes 
in this study. Only eight patients in the doctor’s notes had records of having an adverse effect after 
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administration of IVIG. This accounted for 4% of the study sample but could not be validated by a 
concurrent Adverse Drug Event Report submission. Similarly, the NHLS database had to be perused 
subsequently to determine if LFTs and IGG testing had been requested for patients in the sample. 
Trough IGG should be initiated prior to commencement with IVIG to determine the baseline of IGG in 
replacement therapies. Failure to do this hinders the ability to definitively establish the efficacy of IVIG 
as therapy. In addition, IGG levels should continue post IVIG administration for chronic therapy. Very 
rarely was this good practice met, with only 28 (15%) of 185 patients being tested for IGG trough 
levels and seven of them had primary immunodeficiency and five had cancer. As IVIG is metabolised 
by the liver, LFTs are good indicators of distribution of IVIG and its effects on the liver. Liver function 
tests used to assess the effect of IVIG on liver enzymes were reported in 57 (31%) of the patients  
4.2.3 IVIG expenditure 
Expenditure on IVIG by financial year appears to be increasing year on year as demonstrated in Figure 
2.1 and Table 4.2. The increase in usage is evident over the five years with 2013/2014 being an 
anomaly. As transplants are accounting for an ever-increasing proportion, the lower number of 
transplants in that particular time period could account for that transient dip. The percentage of IVIG 
purchased against the pharmacy expenditure doubled from 2010/2011 to 2011/2012 financial years 
respectively. As use is based entirely on demand and not limited to clinical or formulary restrictions, 
factors like number of in-patients and total admissions in the hospital would need to be considered to 
assess whether the increases shown in this study are a result of the increased patient numbers seen at 
the hospital or are as a result of increased use in patients. Table 4.3 indicates that the number of in-
patients decreased at the period when pharmacy expenditure on IVIG doubled. Over the five-year 
period admissions decreased by approximately 1000 admissions and the in-patient numbers decreased 
by 9000 patients. One could thus conclude that since 92% of all IVIG use was for in-patients, the 
prescribing of IVIG in the 2011/2012 year was not due to overall increases in patient numbers. As 
IVIG is available without restriction in the tertiary facilities in the Western Cape, use is open and 
subjective. The provincial code list/formulary does not specify the indications for which it may be 
used, thereby allowing the use to be solely determined by prescriber demands. 
The cost per patient in the current study sample was considerably more than that of the average cost per 
patient. This excludes any other associated costs and was calculated only from the cost of IVIG, 
demonstrating the huge expense IVIG contributes to the overall cost per patient for this group.  
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4.2.4 Additional limitations to study 
This study, although worthwhile and explorative, also exposed a unique environment not previously 
covered by other existing literature. However, the study was not without its limitations and challenges. 
4.2.5 Challenges faced in the study 
Obtaining a primary diagnosis was difficult in the context of the specialist paediatric service, as most 
patients had multiple co-morbidities. This was compounded by the difficulty of extracting the required 
data retrospectively from the medical records. Across the board notes were difficult to read and many 
details of diagnosis and treatment were absent or missing. ICD10 codes could not be ascertained as 
clinicians did not use this coding in determining the diagnosis and indication for IVIG. As a result of 
the wide variety of clinical indications and difficulty in ascertaining the primary indications for IVIG, 
consultants were asked to verify probable reasons for using IVIG in these very complex multi-morbid 
patients. Some provided evidence and some were uncertain of the use or considered it as ‘last chance’ 
medication. 
Personal communication with the clinicians elucidated the challenges faced in dealing with complex, 
paediatric children presenting with rare and often life-threatening illnesses. Since RCWMCH operates 
as a specialist tertiary referral paediatric facility, the guidance on use is often absent and relies on 
evidence for which not much research undertaken has been undertaken due to the complexities and 
ethics of doing trials on rare illnesses in this vulnerable population. Often, expert opinion on clinical 
cases is the only information available. This has highlighted the need for a more coherent body to 
initiate the standardisation process for use of IVIG.  
Other challenges include duplication of folders for the same patients with differing folder numbers on 
the dispensing database. This created initial errors that were later picked up in the database and lost or 
missing folders. Four attempts were made to retrieve folders after which a patient was described as 
missing. The sample size thus varied by indication (N=171) with 14 folders missing. These 14 patients 
constituted 44 IVIG issues. Only certain information was available for them in the pharmacy records 
allowing patient demographics to be ascertained for some variables. 
A further 14 (8%) patients had uncertain indications for being prescribed IVIG or may be considered as 
in the case of the Cairo study, used because no other therapeutic option was available, lack of a suitable 
alternative or needing an urgent response. The disease ranges in these patients were varied, no trends 
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other than statistic doses could be found and six of these patients were issued IVIG whilst in the 
intensive care unit. IVIG could have been administered as ‘last chance medicine’ in acutely ill patients 
in a last ditch effort to improve outcome. Apart from the registered clinical categories, the unregistered 
ones listed as diagnoses needed to be evaluated for evidence and a clinical recommendation made for 
use in various conditions approved by the Provincial Pharmaceutics and Therapeutics Committee. 
There are varying levels of evidence available for potential use of IVIG. Within a resource constrained 
setting, the thorough evaluation of the evidence-base and a clinical guide to use should be an 
imperative step in IVIG administration. 
4.2.6 Bias and measures to ensure validity 
There were two significant sets of information bias arising from (a) the use of the JAC system and the 
ability to retrieve all the folders; and (b) the interpretation of the diagnoses by the investigator. In the 
former, all pharmacists will at some time or other have issued IVIG via the JAC system, so that the 
electronic record reflects the average accuracies/inaccuracies of all the staff over the past three years. In 
the latter, the investigator will have to interpret a number of usually clinician-specific diagnoses and 
reduce them to an International Classification of Diseases (ICD) 10 recognised diagnoses. Apart from 
the error that arises from the initial diagnosis, the secondary interpretation itself is also error-prone. In 
the latter, the investigator will have had to interpret a number of usually clinician-specific diagnoses 
and allocate them to a diagnostic category. Most clinical notes do not list all diagnoses, let alone the 
primary diagnosis, so that it may not have been clear which indication IVIG was prescribed for in the 
first instance. Due to this, it was not possible to apply International Classification of Diseases (ICD) 10 
diagnostic labels in all cases. 
The challenge in getting and reading off doctors’ notes and diagnoses is a well-documented problem in 
retrospective studies using doctors’ notes as primary or secondary data sources. Differential 
misclassification bias might arise from the fact that specific specialised clinics may themselves already 
be applying cut-offs and are therefore ‘diluting’ the figures for the hospital as a whole in terms of who 
is getting IVIG for what. One of the inherent features of this study was that it only reflected the 
prescribing practices of clinicians working at RCWMCH in the three years, and therefore reflecting 
their prescription and documentation habits.  
Secondary reasoning that may have led to a prescription of IVIG may therefore not always have been 
included, an inherent weakness of a retrospective review. As such, the results will not be generalisable 
62 
to other populations because it is unique to this setting. At the same time, this served as an exploratory 
appraisal of actual paediatric use in an entire tertiary facility in a resource limited setting. Trends in 
usage can assist in determining future trends in usage and projections into infections treated annually 
that warrant the use of IVIG, quantities required as well as establish an initial picture on current usage. 
This information can further be used internally as well as externally for other paediatric populations 
within South Africa as a means of reflection and comparison. 
4.2.6.1 Measures used to ensure validity 
Internal 
The JAC pharmacy database records all issues and returns of drug from the pharmacy to named 
patients or wards/clinics. Data was archived annually in the head office JAC database and available on 
written request. 
• The pharmacy database relies on the manual inputting of all dispensing by pharmacists and 
pharmacy assistants and as such is prone to human error. Human error can result in false 
inputting of data against incorrect patient folder numbers, wards or clinics. 
• Any emergency cupboard issues after hours that have not been recorded and issued from the 
JAC database the following day will escape the data collection in pharmacy. 
• Any stock take where discrepancies in count of polyclonal IVIG occur lends itself to 
manipulation by stock adjustments on the JAC database. However, the past few stock takes 
have shown significant agreement with the JAC database. 
• Any differences/errors in transcribing of data from source (patient folders) to data collection 
sheets and subsequent database (Excel or SPSS), though this is being minimised by dual entry 
and back-checking. 
4.2.6.2 Selection bias 
There is no way to reduce selection bias as purposeful sampling was utilised in this study. The aim was 
to measure trends in usage for the stipulated time period irrespective of other trends at different time 
periods. Thus this was a non-random cross-sectional sample. 
Nevertheless, due to its sample size and that every patient during the study period were included if 
issued IVIG from the pharmacy database, the results presented here are a good indication of the 
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prescribing trends/indications observed at RCWMCH for this population receiving IVIG. It is evident 
that the majority of use is unregistered and seeing that IVIG is a costly therapeutic option, it becomes 
imperative to establish the evidence-base for use when designing a guideline/protocol for the paediatric 
use of IVIG. As compared to most other studies in paediatric IVIG use, which were limited by short 
review times, small sample sizes and /or restricted to specialised care, this study covered 39 months of 
continued usage within a whole hospital. It is important to note that this study was limited to describing 
clinical use by MCC registration status. The analysis of the evidence-base for each unregistered 
indication was beyond the scope of the study and more research is needed to ascertain and qualify this. 
The information gleaned by this study will be utilised by the Pharmacy and Therapeutics Committee to 
establish the criteria that would warrant: 1. use without motivation, 2. use with motivation and 3. use 
for which evidence is sparse and there is no clinical justification for administration. This process has 
already begun as a consequence of this study and clinical heads of departments have been requested to 
supply evidence justifying the need for and use in the clinical categories that are not registered by the 
MCC (Appendix E). The PTC will then forward this information on to the Provincial Pharmacy and 
Therapeutics Committee, where each off-label indication will reviewed and an established guideline 
drawn up for paediatrics. A similar scenario will need to take place in the adult setting. 
4.3 ADDITIONAL RECOMMENDATIONS  
Apart from the recommendations listed in the article and in the additional discussion, the following 
serve as recommendations for future studies that could enlighten, add to or assist in improving the work 
completed in this research. 
1.  A prospective study on IVIG utilisation: As this was a retrospective study, all the data collected 
was obtained from source notes. Consequently, missing information, incorrect data and 
illegibility of notes were some of the challenges encountered in retrospectively describing events. 
In addition ICD10 coding was hindered by the ability to make a definitive diagnosis in some 
instances. A prospective study would add further strength with definite end points and specific 
targets allowing a better quality of data to be analysed. 
2.  Assessing the evidence for each intervention: Secondary studies investigating the scientific 
evidence and literature available globally for each disease intervention would be the next 
progressive step for this research. One would need to consider the evidence by a classification 
system to assist in the drawing up of a protocol/guideline for IVIG use.  
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3.  Subsequent to identifying the evidence available, any gaps in the literature with regards to IVIG 
use in specific diseases will need to be filled by primary studies. As the use by sub-specialties 
was wide and varied by duration, an in-depth analysis of IVIG indication for sub-specialties may 
present more substantial information in leading research within a low to middle-income setting. 
4.  Multihospital or regional setting: It is evident that this research was limited to a unique 
environment in a low to middle-income paediatric setting. Assessing the picture of IVIG usage 
within the Western Cape or in all tertiary/secondary hospitals is crucial for greater representation 
of the population. 
5.  IVIG usage in adults: From the literature reviewed, it was ascertained that the results presented 
on IVIG usage in paediatrics differ substantially from that of adults. This is due to the variance in 
diseases and afflictions affecting the paediatric population as opposed to the adult setting. One 
would need to conduct similar research in an adult facility in the Western Cape or elsewhere 
South Africa to determine the usage of IVIG in adults. The cost implications, dosages, durations 
of therapy, indication for use and adverse effects and monitoring would be interesting to analyse 
in an adult setting and with results compared. 
6.  Subcutaneous immunoglobulin (SCIG) use: There are obvious advantages of using a 
subcutaneous formulation, as opposed to IVIG: The subcutaneous route is easier to administer, 
(less costly in both consumables and potential in-patient time) and has a reduced chance of 
needle-stick injuries. However, there is no subcutaneous IVIG product currently registered with 
the MCC in South Africa. Drug trials on this dosage and formulation within our population could 
garner vital information like costs, ease of convenience, compliance, and efficacy of home 




This study was initiated following the casual observation that IVIG consumption at RCWMCH seemed 
to be increasing year-on-year and the subsequent shortage that necessitated the use of Intraglobin F 
under the section 21 licence. The initial assumption was that the majority of the use at the hospital was 
for registered uses. This assumption was proven wrong, as the analysis of the study period (January 
2009 until 31 March 2012) showed that the majority of use was for unregistered indications, by patient 
numbers, and number of IVIG issues. What was even more revealing was that the biggest growth area 
in use was in liver transplants, increased usage mirrored in increasing use in this clinical area. Whereas 
IVIG has been tried in protean conditions as an immunomodulator, often these conditions are rare, 
resulting in the evidence for its use lacking. Though empirically attractive to use, the cost and clinical 
shortage means that wanton use cannot be encouraged. What this research has shown is that: a) there is 
room for standardisation of IVIG administration practices across conditions for which there is ample 
evidence, both in dosage and duration; b) the pre-/post administration IGG testing should be 
protocolled for the conditions in which IVIG is given as replacement therapy; c) the clinical notes need 
to be clearer on indications for individual therapies and side-effects; and d) there is a need for more 
research on the individual efficacy and effectiveness in a host of current clinical applications. Whereas 
this study did not specifically set out to systematically review the evidence behind each current clinical 
use at RCWMCH, the resultant findings of off-label use have rallied clinicians into starting to develop 
an evidence-based protocol to guide indication, dosage and duration for IVIG (see appendix E). This 
study will hopefully continue to assist with the responsible use of resources at the public health facility 
while optimising the care for those patients who will benefit most from it. 
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NBI’S PROCESS OF IVIG MANUFACTURE 
AND QUALITY CONTROL7 
Voluntary non-remunerated donors (NBI site) 
NBI's products are prepared from pooled human plasma sourced predominantly from non-remunerated healthy blood donors. Blood 
donors in South Africa are those people who voluntarily donate their blood or components to be used in accordance with the Human 
Tissue Act (Act 65 of 1983). 
Donor screening 
A range of questions on a confidential questionnaire determines the prospective donor's medical condition, health and any high-risk 
behaviour patterns. The donor is permanently deferred or deferred for a period of time depending on the answers to the questions.  
Individual donation testing 
All units of blood are individually tested and found non-reactive for hepatitis B surface antigen (HBsAg), antibodies to the hepatitis 
C virus, antibodies to the human immunodeficiency viruses, HIV-1 and HIV-2. 
Approved plasma suppliers 
The acquisition of plasma is predominantly from the South African National Blood Services (SANBS) and Western Province Blood 
Transfusion Service (WPBTS) and other internationally regulated suppliers. 
Pooling of individual plasma units 
Processes such as cold ethanol fractionation, have been introduced to enhance product safety, quality and efficacy. 
Internationally accepted viral inactivation/reduction processes 
The methods of manufacture include effective processes such as solvent-detergent treatment, pH 4 treatment and pasteurisation, 
which have been shown to inactivate the important transfusion transmitted lipid enveloped viruses, including the human 
immunodeficiency viruses (HIV-1 and HIV-2), hepatitis B and hepatitis C viruses.  
Quality assurance for final product release 
NBI plasma products fulfil the registration requirements of the South African regulatory authority, the Medicines Control Council, 
in terms of safety, quality and efficacy.  
This plasma is pooled and must contain plasma from 1000 to 10 000 donors. The plasma undergoes five standard extraction 
processes in the Cohn alcohol fractionation II. These standards must adhere to WHO production criteria for IVIG to ensure that a 
safe, pure product of 90% mononumeric IgG is extracted, free from infections and other contaminant risks to the patient. This 
process can take up to 8 months.  
7 As taken from their site http://www.nbi-kzn.org.za/  
69 










Intravenous immunoglobulin (IVIG) belongs to a group of medicines known as immunising agents. IVIG’s are used to prevent 





This protocol applies to all plan types 
Discovery Health funds intravenous immunoglobulins for the following 
conditions: 
 Kawasaki syndrome 
 Guillian ‘Barre’ syncrome 
 X-linked agammaglobulinemia 
 Swiss-type agammaglobulinemia  
 Hyper IGM syndrome 
 Wiscott-Alrich syndrome 
 Common variable immunodeficiency with recurrent infection 
 Selective deficiency of IgG sub-classes ie selective IgG deficiency with 
recurrent infection 
 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) also 
known as chronic relapsing polyneuropathy 
 Dermatomyositis /Polymyositis 
 Relapsing / remitting multiple sclerosis 
 Myasthenia gravis-acute myasthenic crisis with decompensation 
(respiratory failure or disabling weakness requiring hospital admission) 
 Warm-type Haemolytic Anaemia 
Medical expenses incurred during an approved hospital admission will be paid from the Hospital Benefit, based on the member's 
chosen Discovery Health Plan, subject to preauthorisation. Clinical entry criteria will apply 
Oncology Benefit 
Discovery Health funds intravenous immunoglobulins for :  
 Chronic B-Cell lymphocytic leukaemia with low IgG 
 Multiple Myeloma with hypogammaglobulinaemia 
 Idiopathic thrombocytopenic purpura (ITP) (paediatric) Idiopathic 
thrombocytopenic purpura (ITP) (adult, acute) Idiopathic 
thrombocytopenic purpura (ITP) (chronic refractory 
Medical expenses incurred during an approved hospital admission will be paid from the Oncology Benefit based on the 
member's chosen Discovery Health Plan, subject to preauthorisation. Clinical entry criteria will apply 
Stem Cell Benefit 
Discovery Health will fund Immunoglobulins for: 
 Allogenic Bone Marrow Transplantation (recipient) from the Stem Cell 
Benefit, based on the member’s chosen Discovery Health Plan, subject to 
preauthorisation. Clinical entry criteria apply
Discovery Health does not fund 
Any other condition not in this protocol 
InHouse Schemes 




Approve requests for the following indications without escalation. 
Diagnosis Clinical entry criteria and dosage 
Kawasaki Syndrome Request should be from a paediatrician or immunologist 
 Approve treatment for a maximum of five (5) days only in 
hospital 
Guillian Barre syndrome Request should be from the neurologist, paediatrician or physician 
 Immunoglobulins should be initiated within two weeks of the onset 
of neuropathic symptoms and not later than four weeks. 
 Approve treatment for a maximum of five(5) days only in hospital 
Refer requests for the following indications to DiscoveryCare Oncology Case Managers 
Multiple Myeloma or  Chronic B-Cell 
lymphocytic leukemia with 
hypogammaglobulinaemia(low IgG ) 
Request should be from haematologist or oncologist 
Patient to be registered on the Oncology Programme for this condition and 
with the following history: 
 Recurrent or severe bacterial infection with evidence of 
hypogammaglobulinaemia or 
  Suboptimal response to antigenic stimulation 
Approve immunoglobulins every four weeks for six months from the Oncology
Benefit: 
 If on chemotherapy continue for a further six months 
 If not on chemotherapy : 
o allow six to eight weeks break and request IgG trough levels 
and 
o  If trough levels are normal, do not approve further treatment. If the
trough levels are below normal, continue funding for a further three
months only (total of 9 months) 
Allogenic bone marrow transplantation 
(recipient) 
Request should be from the haematologist or oncologist 
 Patient to be registered on the Oncology Programme 
 For prophylaxis of graft versus host disease 
Approve immunoglobulins from the Stem Cell Benefit for seven days prior 
to transplantation and up to three months thereafter at four months 
Idiopathic thrombocytopenic purpura 
(ITP) (paediatric) 
Request should be from the haematologist or paediatrician 
 IVIG as initial therapy if platelet count < 20,000/ul, especially 
when member has emergency bleeding or is at risk for severe life- 
threatening bleeding; or 
 Failure of other therapies or 
 Member at high risk for post-splenectomy sepsis 
Approve treatment for a maximum of three days in hospital 
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Idiopathic thrombocytopenic purpura 
(ITP) (adult, acute) 
Requests from haematologist or physician for the following indications:  
 Other causes of thrombocytopenia have been ruled out and 
 Severe thrombocytopenia (platelet counts less than 20,000/ul) 
 considered to be at risk for intracerebral haemorrhage, or 
 Management of acute bleeding due to severe thrombocytopenia 
 (platelet counts less than 30,000/ul); or 
 To increase platelet counts prior to invasive major surgical 
procedures (e.g. splenectomy); or 
 Unresponsive to corticosteroid therapy; or 
 To avoid splenectomy 
Approve treatment for maximum of three days in hospital 
Idiopathic thrombocytopenic purpura 
(ITP), chronic refractory 
Requests should be from a haematologist or physician, paediatrician 
 Age of 10 years or older; and 
 Duration of illness of greater than six months; and 
 No concurrent illness or disease explaining thrombocytopenia; 
 and 
 Prior treatment with corticosteroids or splenectomy   has failed; 
or 
 Member is at high risk for post-splenectomy sepsis 
Refer motivational letter/treatment plan requests for the following indications to DiscoveryCare Medical Review 
Team (MRT) 
Warm Type Haemolytic Anaemia Requests should be from haematologists, physicians , paediatricians 
 After failure of or intolerance to: 
o  corticosteroids or Immunosuppressants 
 As a temporising measure prior to splenectomy 
Approve treatment for a maximum of five days in hospital 
X-linked agammaglobulinemia Request should be from the physician, paediatrician or haematologist  
 Markedly reduced or absent serum IgG, IgM, IgA  or Absent B 
lymphocytes in the blood or 
 Suboptimal response to antigenic stimulation eg. tetanus, diphtheria, 
pneumococcal vaccine (adequate response is fourfold 
 increase in antibody titre) 
Approve immunoglobulins every four weeks for 6 months at a time 
Swiss-type agammaglobulinemia Request should be from the physician, paediatrician or haematologist 
Approve immunoglobulins every four weeks for 6 months at a time 
Hyper IgM syndrome Request should be from the physician, paediatrician or haematologist 
 Recurrent respiratory and intestinal infections and 
 Low or absent IgA, IgG, and IgE 
Approve immunoglobulins every four weeks for 6 months at a time 
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Common variable immunodeficiency with 
recurrent infection 
Request should be from the physician or paediatrician 
Other causes of secondary antibody deficiency are excluded eg drug 
induced or nephrotic syndrome 
 Suboptimal response to antigenic stimulation eg tetanus, diphtheria, 
pneumococcal vaccine (adequate response is fourfold increase in 
antibody titre) or 
 Either serum IgG and, IgM below normal 
Approve immunoglobulins every four weeks for 6 months at a time 
Selective deficiency of IgG sub-classes 
i.e. selective IgG deficiency with 
recurrent infection 
Request should be from physician or paediatrician 
 Unexplained recurrent or persistent severe bacterial infections despite 
adequate treatment and 
 Deficiency of one or more IgG subclasses and 
 Suboptimal response to antigenic stimulation eg tetanus vaccine 
Approve immunoglobulins every four weeks for 6 months at a time 
Chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP); also 
known as chronic relapsing 
polyneuropathy 
Request should be from the neurologist, physician or paediatrician 
 Elevated spinal fluid protein, with normal cell count 
 Motor: 
o IVIG given as first line treatment 
 Sensory: (where there is failure, or intolerance to corticosteroids or 
immunosuppressants or are contraindicated ) 
o IVIG may be given as second line 
Approve treatment  for  up to 6 months and review , if responding to 
treatment approve additional 6 months 
Approve immunoglobulins every two –six  weeks for 6 months at a time 
Dermatomyositis /Polymyositis Request should be from the neurologist, physician or paediatrician 
 Patients with muscle weakness or dysphagia who 
 Have failed or are intolerant to corticosteroids or immunosuppressive 
agents 
Approve immunoglobulins every four weeks for 6 months at a time 
Relapsing/remitting multiple sclerosis Request should be from a neurologist 
 Where there is intolerance to standard therapies; or 
 Where standard therapies have failed or are contraindicated 
Approve treatment  for  up to 6 months and review , if responding to 
treatment approve additional 6 months 
Approve immunoglobulins every four weeks for 6 months at a time 
Acute myasthenic crisis with 
decompensation - respiratory failure or 
disabling weakness requiring hospital 
admission 
Request should be from a neurologist or physician 
 Respiratory failure or disabling weakness requiring hospital admission 
and 
 Where there is intolerance to standard therapies, or where standard 
therapies have failed or are contraindicated or 
 As an alternative to plasma exchange in acute exacerbation 
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Disclaimer table 
Discovery Health's coverage policies are developed using a rigorous, evidence-based decision- 
making process, consisting of a clinical and financial filter. The clinical filter uses evidence- 
based literature, the opinions of local and international leaders, and current treatment guidelines 
to ensure that the health care service is safe, ethical, clinically and cost-effective.  Discovery 





















Allogeneic bone marrow transplant NI 1 NI NI NI 1 1.0
Chronic lymphocytic leukemia NI 1 NI 2 2 2 1.8
Idiopathic thrombocytopenic purpura NI 2 NI 2 2 2 2.0
Kawasaki disease NI 2 NI 2 2 2 2.0
Pediatric HIV (to decrease bacterial infections) NI 1 NI 2 2 2 1.8
Primary immunodeficiencies NI 2 NI 2 2 2 2.0
Unlabeled
Acquired hemophilia 0 1 NI 0 NI NI 0.3
Acquired von Willebrand’s disease 0 NI NI 0 NI NI 0.0
Adrenoleukodystrophy 0 0 NI 0 NI NI 0.0
Alzheimer’s disease NI NI NI 0 NI NI 0.0
Amyotrophic lateral sclerosis 0 0 NI 0 NI NI 0.0
Anemia, aplastic 0 NI NI 0 NI NI 0.0
Anemia, hemolytic autoimmune, refractory 1 1 NI 2 NI NI 1.3
Anemia, hemolytic neonatal 1 NI NI 2 NI NI 1.5
Angioedema NI NI NI 0 NI NI 0.0
Antiphospholipid syndrome in pregnancy NI 0 NI 0 NI NI 0.0
Asthma, severe and chronic chest symptoms 0 1 NI 0 NI NI 0.3
Asthma, noncorticosteroid-dependent 0 0 NI 0 NI NI 0.0
Autistic disorder NI 0 NI 0 NI NI 0.0
Autoimmune blistering skin diseases and manifestations of systemic disease NI 1 2 2 2 NI 1.8
Autoimmune inner ear disease NI NI NI 0 NI NI 0.0
Bacterial infections in lymphoproliferative disease NI 1 NI NI NI NI 1.0
Behçet’s syndrome 0 NI NI 0 NI NI 0.0
Cardiomyopathy, acute, dilated 0 0 NI 0 NI NI 0.0
Cerebral infarctions with antiphospholipid antibodies NI 1 NI NI NI NI 1.0
Chronic fatigue syndrome 0 0 NI 0 NI NI 0.0
Chronic inflammatory demyelinating polyneuropathy 2 2 NI NI 2 2 2.0
Churg-Strauss syndrome, allergic granulomatosis NI NI NI 2 NI NI 2.0
Clostridium difficile colitis/pseudomembranous colitis NI 1 NI 0 NI 2 1.0
Congenital heart block 0 NI NI 0 NI NI 0.0
Convulsive syndromes NI NI NI 0 NI NI 0.0
Cystic fibrosis 0 NI NI 0 NI NI 0.0
Dermatitis, atopic NI 0 NI 0 NI NI 0.0
Dermatomyositis, polymyositis 1 1 NI 2 2 2 1.6
Dermatosis, autoimmune blistering 0 NI 2 0 NI NI 0.7
Diabetes mellitus 0 1 NI 0 NI NI 0.3
Diamond-Blackfan anemia 0 NI NI 0 NI NI 0.0
Dysautonomia, acute idiopathic 0 1 NI 0 NI NI 0.3
Eczema NI NI NI 0 NI NI 0.0
Encephalitis, demyelinative brain stem NI 1 NI 0 NI NI 0.5
Encephalomyelitis, acute disseminated 0 1 NI 0 NI NI 0.3
Encephalopathy NI NI NI 0 NI NI 0.0
Endotoxemia 0 NI NI 0 NI NI 0.0
Enteritis, Campylobacter species-induced NI 1 NI NI NI NI 1.0
Enteroviral meningoencephalitis NI 1 NI NI NI NI 1.0
Epidermolysis bullosa acquisita NI NI 2 NI NI NI 2.0
Epilepsy, pediatric intractable 1 1 NI 0 NI NI 0.7
Fetomaternal alloimmune thrombocytopenia NI 1 NI NI NI 2 1.5
Goodpasture’s syndrome NI NI NI 0 NI NI 0.0
Grave’s ophthalmology NI 2 NI NI NI 2 2.0
Continued on next page
Appendix D
Unlabelled Uses of IVIG
(Taken from Leong et al.)
Guillain-Barré syndrome 2 2 NI 2 2 2 2.0
Hemolytic jaundice, neonatal autoimmune NI 1 NI NI NI NI 1.0
Hemolytic transfusion reaction 0 NI NI 0 NI NI 0.0
Hemolytic-uremic syndrome NI NI NI 0 NI NI 0.0
Hemophagocytic syndrome 0 NI NI 0 NI NI 0.0
Hyperimmunoglobulinemia E syndrome NI NI NI 2 2 NI 2.0
IgA deficiency, isolated NI 0 NI NI NI NI 0.0
IgG subclass deficiency with severe infection NI NI NI 2 NI NI 2.0
IgG4 deficiency, isolated NI 0 NI NI NI NI 0.0
IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathy NI 1 NI NI NI NI 1.0
Immunosuppression, secondary to major surgery and disease NI NI NI 2 NI NI 2.0
Inclusion body myositis 0 0 NI 0 NI 1 0.3
Infection prophylaxis, high-risk neonates 1 1 NI 0 2 NI 1.0
Infection prophylaxis, solid organ transplant 1 NI NI NI NI NI 1.0
Infection treatment, adults in surgery/trauma/burns 0 NI NI NI NI NI 0.0
Infection treatment, high-risk neonates 0 NI NI NI NI NI 0.0
Infection treatment, HIV infection (adults) 0 0 NI NI NI NI 0.0
Infection treatment, surgery/trauma 0 NI NI NI NI NI 0.0
Lambert-Eaton myasthenic syndrome 1 1 NI 2 2 2 1.6
Leukemia, acute lymphoblastic 0 NI NI 0 NI NI 0.0
Liver disease, autoimmune NI 1 NI NI NI NI 1.0
Lower motor neuron syndrome 0 NI NI 0 NI NI 0.0
Lumbosacral or brachial plexitis NI 1 NI 0 NI NI 0.5
Malignancy, nonhematologic NI NI NI 0 NI NI 0.0
Miscarriage, recurrent 0 0 NI 0 NI NI 0.0
Multifocal motor neuropathy 1 2 NI 2 2 2 1.8
Multiple myeloma 1 NI NI 2 NI NI 1.5
Multiple sclerosis, monoclonal gammopathy 1 1 NI NI NI 0 0.7
Multiple sclerosis, relapsing-remitting NI NI NI 2 NI 0 1.0
Myalgia, myositis NI NI NI 0 NI NI 0.0
Myasthenia gravis 1 1 NI 2 2 1 1.4
Myelopathy, HTLV-1 associated 0 1 NI 0 NI NI 0.3
Myelopathy, transverse NI NI NI 0 NI NI 0.0
Myocarditis, acute, viral NI 1 NI 0 NI NI 0.5
Necrotizing enterocolitis NI NI NI 0 NI NI 0.0
Neonatal lupus syndromes NI NI NI 0 NI NI 0.0
Nephritic syndrome 0 NI NI 0 NI NI 0.0
Nephropathy, membranous 0 NI NI 0 NI NI 0.0
Nephrotic syndrome 0 NI NI 0 NI NI 0.0
Neuromyelitis optica (Devic’s disease) NI NI NI 0 NI NI 0.0
Neuromyotonia (Isaac’s syndrome) NI NI NI 0 NI NI 0.0
Neurosarcoidosis NI NI NI 0 NI NI 0.0
Neuropathy, demyelinating associated with monoclonal IgM NI 0 NI NI NI NI 0.0
Neuropathy, sensory NI NI NI 0 NI NI 0.0
Neutropenia, immune mediated 1 1 NI 0 2 NI 1.0
Ophthalmopathy, euthyroid 0 NI NI 0 NI NI 0.0
Opsoclonus-myoclonus 0 1 NI 2 NI NI 1.0
Optic neuritis, acute NI NI NI 0 NI NI 0.0
Oral use 0 NI NI 0 NI NI 0.0
Otitis media, recurrent 0 NI NI 0 NI NI 0.0
Paraneoplastic cerebellar degeneration 0 0 NI 0 NI NI 0.0
Paraneoplastic opsoclonus-myoclonus-ataxia associated with neuroblastoma NI NI NI 2 NI NI 2.0
Indication

















Paraproteinemic neuropathy 0 1 NI 0 NI NI 0.3
Parkinson’s disease NI NI NI 0 NI NI 0.0
Parvovirus infection (general) 0 NI NI 2 2 NI 1.3
Pediatric autoimmune neuropsychiatric disorders associated 
with streptococcal infections NI 1 NI 0 NI NI 0.5
Pemphigoid, bullous NI NI 2 NI NI NI 2.0
Pemphigoid, mucous membrane, cicatricial NI NI 2 NI NI NI 2.0
Pemphigus NI NI 2 2 2 2 2.0
Pemphigus foliaceus NI NI 2 NI NI NI 2.0
Pemphigus vulgaris NI NI 2 NI NI NI 2.0
POEMS syndrome 0 0 NI 0 NI NI 0.0
Polyarteritis nodosa NI NI NI 0 NI NI 0.0
Polyneuritis cranialis NI NI NI 0 NI NI 0.0
Postinfectious cerebella ataxia NI 1 NI NI NI NI 1.0
Posttransfusion purpura NI 1 NI 2 NI 2 1.7
Primary immune defect with normogammaglobulinemia and impaired specific 
antibody production NI 1 NI 2 NI NI 1.5
Progressive lumbosacral plexopathy 0 NI NI 0 NI NI 0.0
Pseudomembranous colitis/Clostridium difficile colitis NI 1 NI NI NI 2 1.5
Pure red cell aplasia 1 NI NI 0 NI NI 0.5
Radiculoneuritis, Lyme 0 NI NI 0 NI NI 0.0
Rasmussen’s syndrome 0 1 NI 0 NI NI 0.3
Reiter’s syndrome 0 NI NI 0 NI NI 0.0
Renal failure, acute 0 NI NI 0 NI NI 0.0
Rheumatic fever, acute NI 0 NI NI NI NI 0.0
Rheumatoid arthritis 0 1 NI 0 NI NI 0.3
Rotaviral enterocolitis NI 1 NI NI NI NI 1.0
RSV lower-respiratory-tract infection NI 1 NI NI NI NI 1.0
Scleroderma NI NI NI 0 NI NI 0.0
Sepsis, neonatal NI 1 NI NI NI NI 1.0
Sepsis, postoperative NI 1 NI NI NI NI 1.0
Sinusitis, chronic NI NI NI 0 NI NI 0.0
Stiff-person (Moersch-Woltmann) syndrome NI 1 NI 2 2 2 1.8
Sydenham’s chorea NI NI NI 0 NI NI 0.0
Systemic lupus erythematosus 1 1 NI 2 NI 2 1.5
Systemic vasculitides 1 1 NI 0 NI NI 0.7
Thrombocytopenia, HIV associated NI NI NI 2 NI NI 2.0
Thrombocytopenia, neonatal alloimmune/autoimmune 1 NI NI 2 2 NI 1.7
Thrombocytopenia, nonimmune 0 NI NI 0 NI NI 0.0
Thrombocytopenia, posttransfusion purpura 2 NI NI NI NI NI 2.0
Thrombocytopenia, refractory to platelet transfusion 1 NI NI 0 NI NI 0.5
Thrombocytopenia, TTP/HUS 0 NI NI 0 NI NI 0.0
Tic disorders NI NI NI 0 NI NI 0.0
Toxic epidermal necrolysis, Stevens-Johnson syndrome NI 1 NI 0 NI 1 0.7
Toxic necrotizing fascitis due to group A streptococcal bacteria NI NI NI 2 NI NI 2.0
Toxic shock syndrome, streptococcal or staphylococcal 0 1 NI 2 2 NI 1.3
Transplant, bone marrow, GVHD and infection prevention NI 1 NI NI NI NI 1.0
Transplant, bone marrow, prevention of chronic GVHD NI 0 NI NI NI NI 0.0
Transplant, bone marrow/stem cell, prevention of severe infections with marked 
hypogammagolinemia NI NI NI 2 NI NI 2.0
Transplant, renal, live donor with ABO incompatibility or positive cross-match NI NI NI 2 NI NI 2.0
Transplant, renal, prevention of acute humoral rejection NI 1 NI NI 2 NI 1.5
Indication

















Continued on next page
aScore of 0 = IVIG not recommended, 1 = IVIG may be beneficial, and 2 = acceptable use of IVIG. NI = not included, IgA = immunoglobulin 
A, IgG = immunoglobulin G, IgM = immunoglobulin M, HTLV = human T-cell lymphotropic virus, RSV = respiratory syncytial virus, TTP/HUS = 
thrombotic thrombocytopenia purpura/hemolytic-uremic syndrome, GVHD = graft-versus-host disease, CMV = cytomegalovirus.  
bIVIG may be considered for treatment under certain circumstances; refer to full UHC guidelines for additional information. cMany conditions 
must meet specific criteria; refer to full policy for additional information.  
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Transplant, renal, treatment of acute humoral rejection NI 1 NI NI NI 2 1.5 
Transplant, solid organ, CMV infection NI 2 NI NI 2 NI 2.0 
Urticaria, chronic NI 1 NI 0 NI NI 0.5 
Urticaria, delayed pressure NI 1 NI NI NI NI 1.0 
Uveitis 0 1 NI 0 NI NI 0.3 
Vasculitis associated with other connective tissue disorders NI NI NI 0 NI NI 0.0 
Vogt-Koyanagi-Harada syndrome 0 NI NI 0 NI NI 0.0 
Wegener’s granulomatosis NI NI NI 0 NI NI 0.0 
APPENDIX E: 
PROPOSED INICATIONS FOR THE USE OF INTRAVENOUS 
IMMUNOGLOBULINS AT RCWMCH 
Condition Selected Dose Frequency Evidence / grade 
Primary immunodeficiencies with defective 
antibody production (initiation of IVIG 
replacement therapy restricted to Paediatric 
Infectious Diseases Unit) 
Yes   B, IIb 
Pure red cell aplasia B19 No##$$   A, Ib 
Haemolytic disease of the foetus and newborn 
(isoimmune haemolytic jaundice  in neonates) 
No   C, III 
Auto immune haemolytic anaemia No   C, III 
Neonatal alloimmune thrombocytopenia No$$   C,III 
Post-transfusion purpura No   C, III 
Alloimmune thrombocytopenia, mother Yes   C, III 
Alloimmune thrombocytopenia — neonatal 
therapy 
No$$   C, III 
Auto immune thrombocytopenia No##&&   A, Ia 
Adult HIV associated thrombocytopenia No   A, IB 
Idiopathic thrombocytopenic purpura (<16 
years) 
No   A, Ia 
Evan’s syndrome No   C, III 
Myasthenia gravis No**$$   B, Ia 
Guillain-Barré syndrome No**$$   A, Ia 
Chronic inflammatory demyelinating 
polyradiculoneuropathy 
No   A, Ia 
Paraprotein associated demyelinating 
neuropathy (IgG or IgA) 
No   A, Ia 
Commented [AD1]: $$ = selected cases which would include 
parvovirus infection in immunocompromised cases. 
Commented [AD2]: We suspect that neonatology would take 
issue with this! 
Commented [AD3]: $$ = selected cases. Difficult: Although it’s 
use has met with mixed results, it is cheaper than rituximab and 
would have to be considered for steroid resistant AIHA. 
Commented [AD4]: $$ = selected cases. Active bleeding that is 
not responding to steroids. 
Commented [AD5]: $$ = selected cases. Active bleeding that is 
not responding to steroids. 
Commented [AD6]: $$ = selected cases would include [1] active 
bleeding in patients who are not responsive to steroids [2] intracranial 
or other forms of life-threatening haemorrhage [3] pregnant women 
with contraindications to steroid therapy. 
Commented [AD7]: $$ = selected cases would include [1] active 
bleeding in patients who are not responsive to steroids [2] intracranial 
or other forms of life-threatening haemorrhage. 
Commented [JMW8]: Specialist initiated absolutely – access 
must remain for our patients – we use it in crisis situations 
79 
Multifocal motor neuropathy No   A, Ia 
Lambert-Eaton myasthenic syndrome No   A, Ib 
Toxic epidermal necrolysis Yes   B, IIa 
Dermatomyositis No   A, Ib 
Kawasaki disease Yes   A. Ia 
Chronic lymphocytic leukaemia No   A, Ia 
Multiple myeloma No   A, Ib 
Pneumonitis induced by cytomegalovirus 
following transplantation 
No   A, Ib 
Rasmussen syndrome No   B, IIb 
Encephalitis lethargica Yes    
ADEM / ADEM spectrum conditions No $$    
 
 
** May be approved to prevent ventilation and shorten stay in ICU in patients with decreasing lung 
functions. 
## May be approved to pregnant women with contraindications to steroid therapy. 
$$ may be approved in selected cases. 
&& May be approved for patients with intracranial bleeding 
 
*Grade A: Requires at least one randomised controlled trial as part of a body of literature of overall good 
quality and consistency evaluating the specific recommendation (evidence levels Ia, Ib).  
Grade B: Requires the availability of well conducted clinical studies but not randomised clinical trials on the 
topic of recommendation (evidence levels IIa, IIb).  
Grade C: Requires evidence obtained from expert committee reports or opinions and/or clinical experiences 
of respected authorities; indicates an absence 
  
Commented [JMW9]: Don’t agree – we use it for severe cases 
where ambulation is threatened or there is severe threat to systemic 
health. Should be $$ - paed neuro happy to notify committee is use it.  
Commented [JMW10]: Should be “$$” – beyond surgery there 
is little to do for these patients IVIG is effective in a few and may be 
patients only option. 
Commented [JMW11]: Devastating condition – requires early 
and aggressive intervention. IVIG  is part of this. Patients would be 
under or discussed with (country cases) neuro   
Commented [JMW12]: We manage most successfully with IV 
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Polyvalent intravenous immunoglobulin (IVIG) is registered for specific 
indications in South Africa and is being used off-label for a number of differing 
diseases. The majority of this use has been undocumented. In spite of no 




The aim of the study is to describe indications and frequency of use of IVIG at a 




The main objectives of the study are to determine the usage, demographic 
profile, indication and cost per patient of IVIG in the study period as well as the 
patient outcomes if available. 
 
Study design;  
An observational, cross-sectional descriptive study design will be used. 
 
Setting;  
A paediatric tertiary/ specialist referral centre located in Cape Town in the 
Western Cape. 
 
Study population;  





  2 
Shenaaz Raiman - 9703187 
 
 
Study sample;  
The study involves a convenience sampling technique taken consecutively on a 
named patient basis from pharmacy dispensing records between 2009 and 
2012. 
 
Data collection;  
Primary data will be obtained from the electronic dispensing database of named 
patients issues within the Pharmacy Department. A folder review will be 
conducted to extract all other relevant data. Thereafter the NHLS database will 
be used for collection of other data if not found sufficient in the folder 
review.Consultation with clinicians for verification may ensue. 
 
Statistical methods;  
The data obtained will be summarised using appropriate measures of central 
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1 Introduction /background 
1.1. What is the problem?  
1.1.1. Research Question?  
What were the indications and actual usage of polyvalent human 
immunoglobulin (IVIG) at a paediatric tertiary referral hospital in South Africa 
between 2009 and 2012? 
1.1 What is known so far? 
Intravenous immunoglobulin has been used to treat several groups of 
conditions including primary imunodeficiencies, secondary immunodeficiencies, 
autoimmune diseases and neurological disorders. Several countries including 
the United States, United Kingdom, Canada and Australia1 have published 
evidence-based guidelines for the administration of immunoglobulin 
therapy.,2,3,4 In South Africa, intravenous immunoglobulin is registered for a 
narrow spectrum of indications5. However, beyond these registered indications, 
no evidence-based guideline exists. Individual clinical judgement determines 
consideration and use. Such subjectivity can lead to a very varied and 
occasionally indefensible practice.   
1.2 What needs to be known? 
To date there have been no known publications from sub-Saharan Africa, 
describing the pattern and spectrum of usage of intravenous immunoglobulin, 
neither in adults, nor in children. 
 Red Cross War Memorial Children’s Hospital (RCWMCH) has shown an 
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increasing trend in usage over the last few years. Therefore, to gain an 
understanding into the indications of use of IVIGs at the hospital, a retrospective 
audit on the dosages and indications for use will be completed. 
1.3 Why is the problem important? 
Polyvalent Intravenous Human Immunoglobulin (IVIG) is available in South 
Africa as Polygam® produced by the National Bioproducts Institute which has 
been the sole supplier of human immunoglobulins up to 2010. Recently 
externally produced products have now entered the market.  
In South Africa, high concentrations of IVIG are derived from pooled human 
plasma, sourced primarily from non–remunerated blood donors. Demand has 
increased indicating that either there is a generally longer duration of use or, the 
spectrum of usage has increased placing a higher demand on the supplier. 
Currently most of the plasma harvested in the country goes towards producing 
IVIG. This has meant that of late, plasma derived from blood donors within 
South Africa has been insufficient to meet the need. Hence plasma is now also 
being procured from Germany, thereby increasing the cost and time of 
production.aTo meet the increasing demands, the sole supplier has embarked 
on a major refurbishment process. 
At both national and hospital level, there is no standard policy guiding use and 
duration of treatment other than its registered uses. Anecdotal evidence 
suggests that the unregistered uses might outweigh the registered use. It is also 
unknown if clinical outcomes are measured routinely both for registered and 
a Personal communication: Trisha Chetty, Head: Information of NBI, Sept 2011) 
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unregistered use or whether the intervention of IVIG administration has a 
desired response that is definable for the indication it is proposed for 
 RCWMCH is the only specialist paediatric government hospital in sub-Saharan 
Africa with a catchment area that is undefined due to specialist referrals from all 
of South Africa and beyond. These specialist tertiary and quaternary areas 
involve oncology, haematology, neurology, renal, and dermatology. RCWMCH 
holds 290 beds with a busy out-patient service. RCWMCH has seen 
approximately 28 200 admissions in 2009/ 2010 financial year and 26 400 in 
2010/ 2011. Private medically funded patients tend to also access the highly 
specialised services offered at RCWMCH. Whilst theoretically, polyclonal IVIG 
is restricted in its use within government facilities by the Provincial Code List, it 
is not known for exactly what indications polyclonal IVIG is used for. IVIG is very 
expensive and is one of the top 50 cost drivers in the medicines budget for a 
number of years at RCWMCH (taken from  the electronic dispensing record 
called JAC at the pharmacy department showing annual usage of drugs 2007-
2012). This trend is evident in other tertiary referral centres in the Western Cape 
too, resulting in successively larger percentages of the pharmacy budget being 
attributed to the purchase of IVIG. It is uncertain if there is a greater therapeutic 
need for IVIG, in which case alternate suppliers of the immunoglobulin must be 
sought in order to keep up with supply or production of IVIG from the current 
sole supplier needs to increase. Other aspects that may present itself include 
an inappropriate use (clinically and cost effectively) of IVIG in the presence of 
other suitable alternatives or establishing the need for IVIG as newer 
therapeutic solutions to other disease states. The long-term risks associated 
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with the injudicious use of to IVIG in general are unknown, while the actual 
proportion of hypersensitivity reactions and other associated side effects from 
treatment at RCWMCH also remains undocumented. 
Without all this information, pharmacy and management is unable to formulate 
an evidence-based strategy.  
 How will the study solve the problem?  
Understanding the usage patterns and spectrum of use of IVIG at RCWMCH is 
integral to determining the frequency of off-label use at RCWMCH. An analysis 
of the past indications, evidence for use and outcome including side effects can 
assist in determining rationale for future use and duration of use in a broader 
context. In addition, a pattern of disease profiles in the paediatric setting that 
warrants the use of IVIG (outside the registered use) may be established 
including that of outliers. The study will compare registered use with off-label 
use.  
Finally, this study will aim to calculate the average annual per patient cost of 
IVIG, which will allow future projections in the purchase thereof. Forecasting 
and creating a specific budget for the indications (will allow better control and 
management of IVIG that the Department of Health (DoH) may make use of in 
terms of planning for IVIG expenditure at an academic level in years to come 
Ultimately the aim would be to fuel further studies in this field within South Africa 
to enrich the knowledge base within the context of a developing world and the 
population it feeds and thereby aid future health systems in a collective policy or 
guideline for use of IVIG nationally 
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2 Literature Review 
Polyclonal human IVIG is a plasma protein replacement therapy containing 
large concentrations of varying subclasses of (Immunoglobulin G) IgG 
antibodies as well as minute quantities of (Immunoglobulin A) IgA and 
(Immunoglobulin E) IgE found naturally in human plasma. It is obtained from 
pooling the plasma of not less than 1000 non-remunerated blood donors and 
then subjecting the plasma to a stringent fractionation and pasteurisation 
process to obtain the final useable product.6 These IgG molecules reflect the 
collective acquired immunity of the donor pool from which it is derived.  
Approximately 25 commercially available products are available globally but are 
not considered generic to one another due to the variances in source, 
manufacturing processes and ultimately product.7  These differences include 
varying concentrations of immunoglobulin and IgG subclasses, differing infusion 
rates, side effects and antibody titre. In addition the various IgG formulations 
are thought to include small amounts of soluble CD4, cytokines, soluble 
cytokine inhibitors, major histocompatibility complex and stabilising agents that 
exhibit their own independent effect as determined from the donor plasma 
pool.8 
Consequently, whilst all these products are therapeutically effective, the 
concentration and uses may differ in minor ways in the country in which they 
are registered.9 
The mechanism of action of polyclonal IVIG is multifaceted lending itself as a 
therapeutic medium to a wide array of disease states, as evident from Table 1. 
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Table 1: Mechanism of action of polyclonal IVIG 
• Modulation of complement activation;  
• Saturation of idiotypic antibodies; 
• Suppression of Fc receptors on macrophages and activation of dendritic cells 
to mediate anti-inflammatory effects helping to reduce the severity of the 
autoimmune disease or inflammatory states; 
• Suppression of a multitude of inflammatory mediators including chemokines, 
cytokines and metalloproteinases10,11 
For this reason, IVIG has an important role in the treatment of auto-immune and 
immune deficiency states by conferring a passive immunity, while also acting as 
an immunomodulator. These various mechanisms may be important in the 
different therapeutic uses of IVIG, including (1) replacement therapy for primary 
and secondary immunodeficiencies, i.e. antibody deficiencies, (2) specific 
passive immunotherapy, and (3) management of specific inflammatory and/or 
immunologic disorders. The complete mechanism of action of IgG however is 
not fully understood and further research is on-going with evidence for greater 
therapeutic outcomes with use in other infectious disease states as well as 
other autoimmune conditions coming to the fore.12 
Registered and Non-registered Uses 
IVIG is registered internationally and nationally for only a few specific 
indications. (Fig. 1) At the same time the majority of IVIG use can be attributed 
to the off label use with approximately 150 varied indications documented, as 
tabulated by Leong et al.13 (See Appendix A). IVIG has had a huge impact 
clinically especially in the treatment of some rare disorders in the fields of 
neurology, haematology, immunology, nephrology, rheumatology and infectious 
diseases. The broad spectrum of activity as replacement or booster therapy for 
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Antibody IgG in humans does not preclude its use as adjunct therapy to a 
myriad of disease conditions. 14 
However the lack of sufficient randomized controlled trials speaking for the 
usage of IVIG in many of these unregistered conditions is concerning. 
Internationally some evidence based guidelines have been developed1-4 but 
these do not exist for South Africa as such, usage remains uncontrolled or 
subject to registered restrictions. To what extent this is being monitored is 
unknown. 
Table 2: Current Registered Use of Polyclonal IVIG 2011 in the USA and SA. 
FDA Registered use Polyclonal IVIG 
(US) 




Replacement therapy in primary antibody 
deficiency syndromes. 
 
Chronic lymphocytic leukaemia  
Myeloma or chronic lymphocytic 
leukaemia with severe 
hypogammaglobulinaemia and recurrent 
infections. 
Idiopathic thrombocytopenic purpura For immunomodulation in: 
* Idiopathic Thrombocytopenic Purpura 
(ITP) in children and adults. 
* Kawasaki disease. 
* Guillain Barré Syndrome. 
Allogeneic bone marrow transplant 
 
Allogeneic bone marrow transplantation. 
 
Paediatric HIV Children with congenital AIDS and 
recurrent infections 
Kawasaki disease  
Chronic inflammatory demyelinating 
polyneuropathy (CIDP).  
 
Kidney transplant with a high antibody 
recipient or with an ABO incompatible 
donor 
 
Alzheimers disease still undergoing phase 
III trials) 
 
Only the Gamunex® brand manufactured by Talecris is approved for CIDP (in 
2008; under the U.S. Orphan Drug law provisions; Source: Wikipedia  
Globally, increasing usage has led to concerns of a manufacturing shortfall. 
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Approximately 82 tons of IVIG was consumed worldwide in 2007 and 120 tons 
expected to be used in 2012. The shortage of plasma-derived medicines and in 
particular IVIG has had most impact in developing countries. High costs for 
production, long production times (6-8 months) as well as shortages in plasma 
from available donors contribute to this shortage. In addition both the on- and 
off-label uses are rare indications that health budgets in developing countries 
are not able to allocate sufficient resources towards.15 
South Africa has had a sole supplier of polyclonal IVIG in the form of National 
Bioproducts Institute (NBI). Due to increasing demands for IVIG and other blood 
products, NBI have lately embarked on a major refurbishment process to their 
production plant. As such the supply of IVIG has been further limited. 7NBI is 
reliant on a volunteer blood donor programme for plasma that is screened for 
hepatitis B surface antigen, HIV -p24 antigen, and antibodies to syphilis, HIV-1, 
HIV-2 and hepatitis C. Shortages in supply have resulted in NBI having to 
purchase plasma internationally to keep up with demand. In 2010, other 
registered products like Interferon B entered the market and Octapharma will be 
following shortly. 
South Africa currently has dual public- and private-funded healthcare systems. 
Approximately 84% of all South Africans, generally lower income and 
unemployed citizens, make use of the public health medical service whilst 
higher income groups access their own private medical care.16 
The public system geared towards prioritization key health issues aimed at 
meeting the majority of the public health needs, but cannot fully address 
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individual and rare disease conditions adequately at all times. Levels of health 
care exist in the public system restricting the use of specific drugs to different 
levels of care. In the Western Cape, usage of IVIG is restricted to central and 
tertiary level facilities for paediatrics and specialist usage only. Patients needing 
access to such therapies would have to be referred to these institutes. 
Occasionally secondary level hospitals have issued IVIG but hesitate to do so 
as it erodes the budget of these facilities greatly and requires them to purchase 
IVIG outside the coded restrictions.  
 Polyclonal IVIG is expensive, costing between ZAR 301.60 (2006) and ZAR 
415.94 (2011) per gram IVIG at state level and approximately 20% more in 
private health facilities. Rather than being restricted by a coding list, usage in 
private is determined by what the funder is willing to cover and pay for. Varying 
medical systems offer varying levels of cover and have established norms for 
their own usage. (See Appendix B).  
With clinical research continuously expanding the potential applications of IVIG 
this concern is valid. The broad mechanism of action allows IVIG as a 
therapeutically viable choice and often last resort in many disease and 
infectious states. Whilst attempts have been made to document the 
unregistered use in various institutes internationally, no such audit has been 
documented within South Africa. This information can then been used to 
formulate evidence based guidelines and policies regarding the unregistered 
use of IVIG. 
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3 Purpose of the study 
The aim of the study is to assess the use and indications for use of Intravenous 
immunoglobulin at Red Cross War Memorial Children's Hospital a tertiary 
paediatric hospital in South Africa for periods January  2009 to March 2012 in 
order to develop recommendations for a guideline on future use. 
4 Specific Objectives 
The specific objectives of the study are: 
 
1. To describe the total annual usage of IVIG;  
2. To describe the demographic profile of children who have received 
intravenous immunoglobulin therapy;  
3. To list the indications for usage as recorded in patient folders, and/ or by 
relevant clinician’s judgement. 
4. To correlate the indications for intravenous immunoglobulin therapy to 
registered and off-label use recommendations during this time period; 
5. To estimate the expenditure on immunoglobulin therapy and relate this to the 
total drug expenditure during each financial year; To calculate the annual 
cost and cost per patient for forecasting budgets; and 
6. To identify the main unregistered indications for use that will need to have 
treatment protocols developed for them.  
5 Type of research  
Heath systems research that can be applied clinically in assisting prescribing 
practices. 
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6 Definitions 
There are no extraordinary definitions in this study. 
7 Research Methodology 
7.1 Study Setting 
Red Cross War Memorial Children’s Hospital is the only dedicated paediatric 
tertiary/quaternary hospital located in Cape Town, Western Cape province in 
South Africa. It has approximately 250 000 patient visits a year and is the centre 
for academic excellence in training, teaching and child healthcare as well as 
playing a pivotal role in Africa for the treatment of life limiting, life threatening 
and complex illnesses in children. As a consequence it sees specialist referrals 
from not only the Western Cape but other parts of South Africa and Africa. 
7.2 Study Design 
An Observational, cross-sectional descriptive study design will be used. 
7.3 Target Population 
Paediatric patients treated with polyclonal IVIG in tertiary care within South 
Africa.  
7.4 Study population 
All patients who were issued polyclonal IVIG, both as outpatients or inpatients 
at RCWMCH.  
7.4.1 Inclusion Criteria 
The inclusion criteria are: 
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• All patients issued or administered polyclonal IVIG between 1st January 
2009 and 31 March 2012 as in-patients or out-patients from RCWMCH 
as based on dispensing data from the JAC dispensing programme in 
pharmacy; 
• All issues from JAC data system of polyclonal intravenous 
immunoglobulin (Polygam® and Intraglobin F®) Both Private and Public 
patients irrespective of age that have been issued polyclonal IVIG from 
RCWMCH pharmacy data as in-patient or out-patients in the stipulated 
time periods; and 
• Emergency cupboard issues for after hours as recorded on a named 
patient basis in the pharmacy dispensing system. 
 
7.4.1 Exclusion Criteria 
The exclusion criteria are: 
• Any unknown administration of IVIG not recorded in pharmacy 
dispensing systems in the stipulated time period;  
• Any other issue of monoclonal intravenous or intramuscular 
immunoglobulin e.g. Intragam®, basiliximab, ATG®, Rabigam®, 
Vazigam®, Tetagam® Habigam® etc.; 
• Any lending of stock to other institutes that are recorded or not recorded  
in the pharmacy dispensing system; and 
• Any incidental usage of polyclonal IVIG by patients at RCWMCH in the 
stipulated time period that has not been issued and recorded in the 
dispensing system i.e. use/administration of private stock. 
7.5 Study Sample 
The study  involves a convenience sampling technique taken consecutively on a 
named patient basis from pharmacy dispensing records between 2009 and 
2012. Data in a 3 year period is being assessed from the pharmacy database 
(JAC) of IVIG issues to different parts of the hospital. As this study is the first 
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known study of actual usage of polyclonal IVIG in a hospital in South Africa, it 
serves as an exploratory analysis of the current usage within a paediatric 
hospital. It is estimated that the last 3 financial years (containing approximately 
6070 issues of polyclonal IVIG annually) will provide an adequate picture of 
current usage and trends. A larger and therefore older sample, e.g. looking 
back 5 - 10 years, might not reflect current prescription practice.  
7.5.1 Method of selecting sample 
The last completed 3 years, 2009, 2010,2011 and until March 2012 are being 
used as the sample. 
7.5.2 Size of sample 
Approximately 70 patients of IVIG annually from periods 2009 to March 2012  
per year, i.e. approximately 200 patients in the total review.  
7.6 Data sources 
Data will be derived from the following sources: 
• A list of named patient issues will be collected from the pharmacy 
dispensing database (JAC). 
• The folders of the identified patients will be dawn and the data extracted 
per patient onto the data extraction form. (See Appendix C). 
• Additional data not found in folders such as results of liver function tests, 
blood counts, Immunoglobulin G (IGG) trough testing and HIV status will 
be obtained from the National Health Laboratory Services (NHLS) data-
base at the hospital. 
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• Relevant clinicians will be consulted informally to determine indication for 
use if necessary. 
7.6.1 Measurement instruments / Data Collection Techniques 
The JAC Database of polyclonal IVIG issues within the past 5 years is available 
and has been archived in an Excel™ spread sheet. This spread sheet will be 
converted to pivot tables to look at varying outcome variables and subsequently 
interpreted and described. This database will also form the primary basis of the 
folder review. 
Appendix C shows the Data Collection Sheet that will be used to extract the 
data from patient folders. The final collected data will be dual inputted into an 
Excel™ database and compared for validity. The final product will be converted 
into an SPSS® database for further analysis and descriptions. 
Measures to ensure validity 
7.6.2 Internal 
The JAC pharmacy database records all issues and returns of drug from the 
pharmacy to named patients or wards/clinics. Data is archived annually in the 
head office JAC database and available on written request. 
• The pharmacy database relies on the manual inputting of all dispensing 
by pharmacists and pharmacy assistants and as such is prone to human 
error. Human error can result in false inputting of data against incorrect 
patient folder numbers, wards or clinics. 
• Any emergency cupboard issues after hours that have not been recorded 
and issued from the JAC database the following day will escape the data 
collection in pharmacy. 
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• Any stock take where discrepancies in count of polyclonal IVIG occur 
lends itself to manipulation by stock adjustments on the JAC database. 
However, the past few stock takes have shown significant agreement 
with the JAC database. 
• Any differences/errors in transcribing of data from source (patient folders) 
to data collection sheets and subsequent database (Excel or SPSS), 
though this is being minimised by dual entry and back-checking. 
7.6.3 Reduction of bias 
7.6.3.1 Selection bias 
There is no way to reduce selection bias as purposeful sampling is being 
utilised in this study. The aim is to measure trends in usage for the stipulated 
time period irrespective of other trends at different time periods. Thus this will 
be a non-random cross-sectional sample. 
7.6.3.2 Information bias   
There are two significant sets of non-differential bias arising from (a) the use of 
the JAC system and the ability to retrieve all the folders and (b) the 
interpretation of the diagnoses by the investigator. In the former, all pharmacists 
will at some time or other have issued IVIG via the JAC system, so that the 
electronic record reflects the average accuracies/ inaccuracies of all the staff 
over the past three years. In the latter, the investigator will have to interpret a 
number of usually clinician specific diagnoses and reduce them to a standard 
recognisable diagnosis. To do this, consultation with the relevant clinician, if 
available, will be done to minimise misinterpretation of diagnoses. Apart from 
the error that arises from the initial diagnosis, the secondary interpretation itself 
is also error-prone. 
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Differential misclassification bias might arise from the fact that specific 
specialised clinics may themselves already be applying cut-offs and are 
therefore “diluting” the figures for the hospital as a whole in terms of who is 
getting IVIG for what. In addition, as some of the treatments might be 
controversial, there may be a higher emergency cupboard use of IVIG rather 
than pharmacy ordered IVIG, thereby circumventing the patient-recording 
mechanism of the JAC system. 
7.6.4 External Validity / Generalisability 
One of the inherent features of this study is that it will only reflect the prescribing 
practices of clinicians working at RCWMCH in the past three years. As such, 
the results will not be generalizable to other populations because unique to this 
setting. At the same time, this will serve as an exploratory appraisal of actual 
paediatric use in a tertiary setting. Trends in usage can assist in determining 
future trends in usage and projections into infections treated annually that 
warrant the use of IVIG, quantities required as well as establish an initial picture 
on current usage. This information can be used further internally as well as 
externally to other paediatric populations within South Africa as a means of 
reflection and comparison. 
7.7 List of Variables  
A complete list of variables to be measured is listed under appendix (See 
Appendix C) in the Data collection sheet. The main variables are listed below. 
• Age in years: discrete 
• Sex: Binary 
• Mass: continuous 
• Race: Nominal 
• Patient profile: Nominal 
• HIV Status: Nominal 
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• Indication for use: Nominal 
• Quantity prescribed: 
continuous 
• Dates issued: continuous 
• Amount issued: continuous 
• Wastage: continuous 
7.8 Plan for Data collection 
The captured data from JAC is a computer-based pharmacy dispensing 
platform, where all the variables are automatically captured in real time, 
archived and are transferred to a spread sheet. The manually obtained data 
collection sheets will be dual entered into an Excel™ 2010 (Microsoft 
Corporation) spread sheet, validated and plotted per annum. As described 
above, the JAC data will form the basis for the folder search. All patients 
identified via the JAC database will have their folders drawn and the data 
extracted as per the standard data extraction form. There will be three attempts 
to retrieve a folder within the three-month data collection period, after which it 
will be deemed to have been “lost” for purposes of this study.  
7.9 Plan for Data handling/ processing 
Any ambiguity in data interpretation will be reviewed by an independent person 
from the study and the final assessment made by consensus. If vital data fields 
are missing, such as age, body weight or diagnosis, that element will not be 
included in the section requiring that analysis, but could be used for the overall 
calculations. 
It will then be analysed in SPSS® (IBM Corporation). The services of a 
statistician will be utilised to confirm the appropriateness of the statistical tests 
utilised and check any trend analyses. 
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All paper records will be stored in a secure, locked, fire-proof filing cabinet at 
the researcher’s office. Electronic records will be pass-phrase protected using a 
commercial encryption technique and backed-up daily in a whole drive pass-
phrase protected external hard drive, kept separate from the first database and 
stored in a fire-proof filing cabinet. Two different external hard drives will be 
used for the daily backup and alternated to allow for a reliable data record in 
case of hard drive failure. 
7.10 Statistical methods 
7.10.1 Descriptive statistics 
Most of the statistics in the study will be descriptive, categorising the clinical 
uses into broad categories. The data obtained will be summarised using 
appropriate measures of central tendency and dispersion and presented in 
appropriate tables and graphs. Simple statistics for the Table 1 summary of 
patient characteristics, listing 95% CI, mean and median will be outlined. In 
addition, there will be summaries of the average duration of treatment, dose of 
treatment per kilogram body weight and average cost per patient year by year.  
7.10.2 Analytic statistics 
As this is an observational study, analytical statistics will not be utilised. 
8  Ethical Considerations 
8.1.1  Institutional Ethical Review Board 
This study will be conducted with due regard to the ethical principles laid out in 
the Declaration of Helsinki and Good Clinical Practice (GCP). It will be 
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submitted for expedited review to the Human Research ethics Committee of 
both RCWMCH and the University of KwaZulu-Natal (UKZN) Biomedical 
Research Ethics Committee. This is a low-risk study from an ethics point of 
view, as it is essentially a retrospective record review, including the few months 
of data gathered in 2012, as it is an observational study, gathering the data 
relating to the cases “after the fact”. In addition, for the purposes of the analysis 
and publication, all patient-level data will be anonymised, with a master-
identification sheet kept separately and only accessible to the principal 
investigator. 
8.1.2  Permissions 
This research project will be registered with the UKZN Postgraduate Education 
Committee for academic purposes. As RCWMCH is a government-run 
healthcare facility, in addition to the Institutional Review Board, permission will 
have to be obtained from the head of the institution, Dr L Lunga, as well as the 
Provincial Research Committee. Only after having obtained these permissions 
will the study commence. 
8.1.3 Informed Consent and Information  
We will request a waiver of informed consent, as this is a retrospective record 
review, as outlined above.  
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9 Work Plan 
9.1  Budget 
 
Budget  
April 2012 –July2013 
Item Description  Unit cost No of 
Units 
Total cost 
Consumables     
1. specialized 
services 
Statistician R 350.- / h 10h R 3 500.- 




Papers, clipboards, photocopies 
to produce the 2-page data sheet 
for  240 study samples 
R 500.- 1 R 500.- 




Binders, copies of data reports 
with cover letters x 2 
 1 R 400.- 
Research travel     






2. Travel to 
supervisor 
 
Three visits to Durban for 
Supervisor meetings and major 
reviews 
R2000.- 3 R6 000.- 
Minor research 
equipment 
    
1.  3G Internet access via dongle R 1000.- 1 R 1 000.- 
2.  External Hard Drives (500GB) R 650.- 4 R 2 600.- 
3.  Netbook R 4600.- 1 R 4 600.- 
 
Sub-Total 
   R 19 410.- 
Total 10% safety factor included   R 21 351.- 
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9.2 Study period / Time lines  




X        
Ethics 




 X       
Creating patient 
lists   X      
Obtaining 
folders & data 
extraction 
  X X X    
Statistical 
Analysis      X   
Compilation of 
final report      X X  
Submission of 
final Thesis       X  
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APPENDIX G: 
DATA COLLECTION SHEET 
THE ADMINISTRATION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) AT RED 
CROSS CHILDREN’S HOSPITAL FROM 2009 TO 2012 
Demographic Data Data Capturer 
Date of birth   
Study number   
Sex   
Race Black     White   Coloured  Indian  Other:  
HIV status if available   
Intravenous immunoglobulin – first time point from  2009  
Mass (kg to one decimal place) at the point of first 
administration from 1st April 2009 onwards 
  
Age (years and months to one decimal place) at 
time of administration of first dose in 2009 or 
onwards 
  
Indication for intravenous immunoglobulin therapy    
Primary Diagnosis    
Secondary Diagnosis   
Other diagnoses   
Amount (grams) prescribed and duration of 
treatment 
  
Amount (grams) issued by pharmacy 
 
1 gram 3 gram 6 gram 12 gram 
    
Wastage   
Concentration administered (grms/kg)   
Inpatient  / outpatient administration 
Ward initiated 
  
Adverse events (Yes 2/No 1/unknown 0)   
Adverse events – describe, include date and time 
and relationship to IVIG infusion 
  
Repeat immunoglobulin therapy subsequently  
Was IVIG repeated during 2009 or thereafter 
(Yes/No) 
  
If yes, how many times during 2009 or thereafter   
List dates, amount prescribed, amount issued, concentration administered   
Date Prescribed (grms) Issued (grms) Concentration (grms/kg body mass) Wards 
     
     
     
110 
     
     
     
     
     
     
     
     
     
Has the patient responded favourably as judged 
by the clinician in notes (Yes 2/No 1/unknown 0) 
  
Have trough IgG concentrations been assessed 
(Yes 2/ No 1) as from laboratory source. 
  
Level of IGG   
Level of IGA   
Level of IgM   
Has an appropriate response been made to the 
trough level (Yes 2/No 1/unknown 0) 
  
Has liver functions been monitored regularly (Yes 
2/No 1/unknown 0) 
  
Adverse events (Yes 2/No 1/unknown 0)   
Adverse events – describe, include date and time 
and relationship to IVIG infusion 
  
Previous IVIG administration – before 2009  
Has the patient received IVIG previously (Yes 
2/No 1/unknown 0) 
  
If yes, since when (date)   
If yes, frequency of administration   
Has the patient responded favourable as judged 
by the primary clinician (Yes 2/No 1/unknown 0) 
  
Has trough IgG concentration been assessed 
(Yes 2/No 1/unknown 0) 
  
Has liver functions been monitored regularly (Yes 
2/No 1/unknown 0) 
  
Adverse events  (Yes/No)   
Adverse events – describe, include date and time 
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